{
    "base": [
        "MDCbase"
    ],
    "metatada": {
        "mainTitle": "OPDIVO® (nivolumab)"
    },
    "variables": {
        "config:track:menu": {
            "track": {
                "objectid": "1",
                "type": "external/menu",
                "custom": "Prescribing Information [menu]"
            }
        },
        "page:default": {
            "title": "MD Chat – OPDIVO® (nivolumab)"
        }
    },
    "configuration": {
        "colorSet": {
            "dark": "666",
            "teal": "58ccc9",
            "grey": "e1e5e3",
            "blue": "58a6dc",
            "white": "ffffff",
            "light-blue": "528cbf",
            "b-blue": "4bacc6",
            "primary": "E1ECF9",
            "secondary": "003B5C",
            "third": "887a77"
        },
        "classes": {
            "contentBody": "grey-color-bg",
            "contentWrapper": "white-color-bg"
        },
        "login": {
            "enabled": false,
            "username": "some_user_name",
            "password": "some_complicated_password"
        },
        "includes": {
            "stylesheets": [
                "https://c.mdchat-usa.com/programs/130201338/css/general27.css"
            ]
        },
        "manifest": {
            "pages": [
                "casey"
            ],
            "setup": {
                "first": "casey"
            }
        }
    },
    "features": {
        "isi": {
            "class": "white-color-bg dark-grey-color-font",
            "logo": "",
            "text": "<p id='lesponsor'></p>",
            "position": "top",
            "scroll": false,
            "scrollOnce": false,
            "layout": "bottom",
            "height": "22%",
            "disclaimer": "<a class='link-1' href='https://packageinserts.bms.com/pi/pi_opdivo.pdf' target='_blank' class='track link1' style='color: white;background-color: #003B5C;height: 40px;line-height: 40px;width: 250px;text-align: center;border-right: 1px solid white;position: fixed; display: block; top: 0px; left: 39px;z-index:999;'>U.S. Full Prescribing Information</a><a href='https://packageinserts.bms.com/medguide/medguide_opdivo.pdf' target='_blank' class='track link-2' style='color: white;background-color: #003B5C;height: 40px;line-height: 40px;width: 160px;text-align: center;position: fixed; display: block; top: 0px; left: 289px;z-index:999;'>Medication Guide</a><div style='text-align: center;'><a class='referenceMain morebtn' id='modalisi' style='background-color: gray;color: white;padding: 8px 15px;text-align: center;cursor:pointer;border-radius: 5px;'>Indication</a></div><p style='float: right;font-size: 14px !important;'>Scroll down for more ISI</p><h4 style='color: #024667'>IMPORTANT SAFETY INFORMATION</h4><p style='color: #024667; margin-bottom: 0px;font-weight: bold;'>Immune&#8209;Mediated Pneumonitis</p><ul> <li>OPDIVO can cause immune&#8209;mediated pneumonitis. Fatal cases have been reported. Monitor patients for signs with radiographic imaging and for symptoms of pneumonitis. Administer corticosteroids for Grade&nbsp;2 or more severe pneumonitis. Permanently discontinue for Grade&nbsp;3 or&nbsp;4 and withhold until resolution for Grade&nbsp;2. In patients receiving OPDIVO monotherapy, fatal cases of immune&#8209;mediated pneumonitis have occurred. Immune&#8209;mediated pneumonitis occurred in 3.1%&nbsp;(61/1994) of patients.</li></ul><p style='color: #024667; margin-bottom: 0px;font-weight: bold;'>Immune&#8209;Mediated Colitis</p><ul> <li>OPDIVO can cause immune&#8209;mediated colitis. Monitor patients for signs and symptoms of colitis. Administer corticosteroids for Grade&nbsp;2 (of more than 5&nbsp;days duration), 3, or 4 colitis. Withhold OPDIVO monotherapy for Grade&nbsp;2 or 3 and permanently discontinue for Grade&nbsp;4 or recurrent colitis upon re&#8209;initiation of OPDIVO. In patients receiving OPDIVO monotherapy, immune&#8209;mediated colitis occurred in 2.9% (58/1994) of patients.</li></ul><p style='color: #024667; margin-bottom: 0px;font-weight: bold;'>Immune&#8209;Mediated Hepatitis</p><ul> <li>OPDIVO can cause immune&#8209;mediated hepatitis. Monitor patients for abnormal liver tests prior to and periodically during treatment. Administer corticosteroids for Grade&nbsp;2 or greater transaminase elevations. Withhold OPDIVO for Grade&nbsp;2 and permanently discontinue OPDIVO for Grade&nbsp;3 or 4. In patients receiving OPDIVO monotherapy, immune&#8209;mediated hepatitis occurred in 1.8%&nbsp;(35/1994) of patients.</li></ul><p style='color: #024667; margin-bottom: 0px;font-weight: bold;'>Immune-Mediated Endocrinopathies</p><ul> <li>OPDIVO can cause immune&#8209;mediated hypophysitis, immune&#8209;mediated adrenal insufficiency, autoimmune thyroid disorders, and Type 1 diabetes mellitus. Monitor patients for signs and symptoms of hypophysitis, signs and symptoms of adrenal insufficiency, thyroid function prior to and periodically during treatment, and hyperglycemia. Administer hormone replacement as clinically indicated and corticosteroids for Grade&nbsp;2 or greater hypophysitis. Withhold for Grade&nbsp;2 or 3 and permanently discontinue for Grade&nbsp;4 hypophysitis. Administer corticosteroids for Grade&nbsp;3 or 4 adrenal insufficiency. Withhold for Grade&nbsp;2 and permanently discontinue for Grade&nbsp;3 or 4 adrenal insufficiency. Administer hormone&#8209;replacement therapy for hypothyroidism. Initiate medical management for control of hyperthyroidism. Withhold OPDIVO for Grade&nbsp;3 and permanently discontinue for Grade&nbsp;4 hyperglycemia.</li> <li>In patients receiving OPDIVO monotherapy, hypophysitis occurred in 0.6%&nbsp;(12/1994)&nbsp;of patients. In patients receiving OPDIVO monotherapy, adrenal insufficiency occurred in 1%&nbsp;(20/1994) of patients. In patients receiving OPDIVO monotherapy, hypothyroidism or thyroiditis resulting in hypothyroidism occurred in 9%&nbsp;(171/1994) of patients. Hyperthyroidism occurred in 2.7%&nbsp;(54/1994) of patients receiving OPDIVO monotherapy. In patients receiving OPDIVO monotherapy, diabetes occurred in 0.9%&nbsp;(17/1994) of patients.</li></ul><p style='color: #024667; margin-bottom: 0px;font-weight: bold;'>Immune-Mediated Nephritis and Renal Dysfunction</p><ul> <li>OPDIVO can cause immune-mediated nephritis. Monitor patients for elevated serum creatinine prior to and periodically during treatment. Administer corticosteroids for Grades&nbsp;2-4 increased serum creatinine. Withhold OPDIVO for Grade&nbsp;2 or 3 and permanently discontinue for Grade&nbsp;4 increased serum creatinine. In patients receiving OPDIVO monotherapy, immune&#8209;mediated nephritis and renal dysfunction occurred in 1.2%&nbsp;(23/1994) of patients.</li></ul><p style='color: #024667; margin-bottom: 0px;font-weight: bold;'>Immune-Mediated Skin Adverse Reactions</p><ul> <li>OPDIVO can cause immune-mediated rash, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), some cases with fatal outcome. Administer corticosteroids for Grade&nbsp;3 or 4 rash. Withhold for Grade&nbsp;3 and permanently discontinue for Grade&nbsp;4 rash. For symptoms or signs of SJS or TEN, withhold OPDIVO and refer the patient for specialized care for assessment and treatment; if confirmed, permanently discontinue. In patients receiving OPDIVO monotherapy, immune&#8209;mediated rash occurred in 9% (171/1994) of patients.</li></ul><p style='color: #024667; margin-bottom: 0px;font-weight: bold;'>Immune-Mediated Encephalitis</p><ul> <li>OPDIVO can cause immune-mediated encephalitis. Evaluation of patients with neurologic symptoms may include, but not be limited to, consultation with a neurologist, brain MRI, and lumbar puncture. Withhold OPDIVO in patients with new&#8209;onset moderate to severe neurologic signs or symptoms and evaluate to rule out other causes. If other etiologies are ruled out, administer corticosteroids and permanently discontinue OPDIVO for immune&#8209;mediated encephalitis. In patients receiving OPDIVO monotherapy, encephalitis occurred in 0.2%&nbsp;(3/1994) of patients. Fatal limbic encephalitis occurred in one patient after 7.2&nbsp;months of exposure despite discontinuation of OPDIVO and administration of corticosteroids.</li></ul><p style='color: #024667; margin-bottom: 0px;font-weight: bold;'>Other Immune-Mediated Adverse Reactions</p><ul> <li>Based on the severity of the adverse reaction, permanently discontinue or withhold OPDIVO, administer high-dosecorticosteroids, and, if appropriate, initiate hormone-replacement therapy. Across clinical trials of OPDIVO, the following clinically significant immune-mediated adverse reactions, some with fatal outcome, occurred in &lt;1.0% of patients receiving OPDIVO: myocarditis, rhabdomyolysis, myositis, uveitis, iritis, pancreatitis, facial and abducens nerve paresis, demyelination, polymyalgia rheumatica, autoimmune neuropathy, Guillain-Barré syndrome, hypopituitarism, systemic inflammatory response syndrome, gastritis, duodenitis, sarcoidosis, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), motor dysfunction, vasculitis, and myasthenic syndrome.</li> <li>If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt&#8209;Koyanagi&#8209;Harada&#8209;like syndrome, which has been observed in patients receiving OPDIVO and may require treatment with systemic steroids to reduce the risk of permanent vision loss.</li></ul><p style='color: #024667; margin-bottom: 0px;font-weight: bold;'>Infusion Reactions</p><ul> <li>OPDIVO can cause severe infusion reactions, which have been reported in &lt;1.0% of patients in clinical trials. Discontinue OPDIVO in patients with Grade 3 or 4 infusion reactions. Interrupt or slow the rate of infusion in patients with Grade 1 or 2. In patients receiving OPDIVO monotherapy as a 60&#8209;minute infusion, infusion-related reactions occurred in 6.4% (127/1994) of patients. In a separate study in which patients received OPDIVO monotherapy as a 60&#8209;minute infusion or a 30&#8209;minuteinfusion, infusion-related reactions occurred in 2.2% (8/368) and 2.7% (10/369) of patients, respectively. Additionally, 0.5% (2/368) and 1.4% (5/369) of patients, respectively, experienced adverse reactions within 48 hours of infusion that led to dose delay, permanent discontinuation or withholding of OPDIVO.</li></ul><p style='color: #024667; margin-bottom: 0px;font-weight: bold;'>Embryo-Fetal Toxicity</p><ul> <li>Based on its mechanism of action, OPDIVO can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with an OPDIVO-containing regimen and for at least 5 months after the last dose of OPDIVO.</li></ul><p style='color: #024667; margin-bottom: 0px;font-weight: bold;'>Lactation</p><ul> <li>It is not known whether OPDIVO is present in human milk. Because many drugs, including antibodies, are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from an OPDIVO&#8209;containing regimen, advise women to discontinue breastfeeding during treatment.</li></ul><p style='color: #024667; margin-bottom: 0px;font-weight: bold;'>Serious Adverse Reactions</p><ul> <li>In Checkmate 017 and 057, serious adverse reactions occurred in 46% of patients receiving OPDIVO (n=418). The most frequent serious adverse reactions reported in &ge;2% of patients receiving OPDIVO were pneumonia, pulmonary embolism, dyspnea, pyrexia, pleural effusion, pneumonitis, and respiratory failure.</li></ul><p style='color: #024667; margin-bottom: 0px;font-weight: bold;'>Common Adverse Reactions</p><ul> <li>In Checkmate 017 and 057, the most common adverse reactions (≥20%) in patients receiving OPDIVO (n=418) were fatigue, musculoskeletal pain, cough, dyspnea, and decreased appetite.</li></ul><p style='margin-top:15px;'>Please see <a href='https://packageinserts.bms.com/pi/pi_opdivo.pdf' class='track' style='color:#003B5C;font-weight:bold;' target='_blank'>U.S. Full Prescribing Information</a> for OPDIVO. </p><img src='https://c.mdchat-usa.com/programs/130201338/img/logo2.png' style='width: 220px;margin-bottom: 10px;'><p style='font-size:12px!important;'>&copy; 2018 <nobr>Bristol-Myers</nobr> Squibb Company. All rights reserved.</p><p style='font-size:12px!important;margin-top:15px;'>OPDIVO<sup>&reg;</sup>, Access Support<sup>&reg;</sup>, and the related logos are registered trademarks of <nobr>Bristol-Myers</nobr> Squibb Company.</p><p style='margin-top:15px;font-size:12px!important;'><nobr>1506US1803107-01</nobr>  <nobr>08/18</nobr></p>",
            "jobcode": ""
        },
        "menu": [
            {
                "label": "<span style='font-weight:400;'>U.S. Full Prescribing Information</span>",
                "type": "external",
                "link": "https://packageinserts.bms.com/pi/pi_opdivo.pdf",
                "use": [
                    "config:track:menu"
                ]
            },
            {
                "label": "<span style='font-weight:400;'>Medication Guide</span>",
                "type": "external",
                "link": "https://packageinserts.bms.com/medguide/medguide_opdivo.pdf",
                "use": [
                    "config:track:menu"
                ]
            },
            {
                "label": "<span style='font-weight:400;'>References</span>",
                "type": "modal",
                "html": "<div class='references-list'><h1 style='font-size:16px!important'>References</h1><p style='font-size:14px!important;'>OPDIVO [package insert]. Princeton, NJ: BristolMyers Squibb <nobr>Company; 2018.</nobr></p><p style='font-size:14px!important;'>Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous <nobr>non-small-cell</nobr> lung cancer. <em>N Engl J Med.</em> <nobr>2015;373:1627-1639.</nobr></p><p style='font-size:14px!important;'>Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced <nobr>squamous-cell</nobr> <nobr>non-small-cell</nobr> lung cancer. <em>N Engl J Med.</em> <nobr>2015;373:123-135.</nobr></p><p style='font-size:14px!important;'>Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. <em>N Engl J Med.</em> <nobr>2015;373(17):1627-1639</nobr> [supplementary appendix].</p><p style='font-size:14px!important;'>Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced <nobr>squamous-cell</nobr> <nobr>non-small-cell</nobr> lung cancer. <em>N Engl J Med.</em> <nobr>2015;373(2):123-125</nobr> [supplementary appendix].</p><p style='font-size:14px!important;'>Felip E, Gettinger S, Burgio MA, et al. <nobr>Three-year</nobr> <nobr>follow-up</nobr> from <nobr>CheckMate 017/057:</nobr> nivolumab versus docetaxel in patients with previously treated advanced <nobr>non-small</nobr> cell lung cancer. Poster presentation at ESMO 2017. Abstract 1301 PD.</p><p style='font-size:14px!important;'>Long G, Tykodi S, Schneider J, et al. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer [published online ahead of print September&nbsp;12, 2018]. <em>Ann Oncol.</em> 2018; <nobr>doi.org/10.1093/annonc/mdy408.</nobr></p></div>"
            },
            {
                "label": "<span style='font-weight:400;'>Privacy Policy</span>",
                "type": "external",
                "link": "https://mdchat-usa.com/privacy"
            },
            {
                "label": "<span style='font-weight:400;'>Contact Us</span>",
                "type": "modal",
                "html": "<h1>Contact Us</h1><p><p class='normal'>NuMedis Publishing<br>1140 Avenue of the Americas, 14th Floor, Suite C<br>New York, NY 10036<br><a href='mailto:info@mdchat-usa.com' style='text-decoration:none; color:#337ab7 !important' target='_blank'>info@mdchat-usa.com</a></p>"
            }
        ],
        "navigation": {
            "type": "headline",
            "displayProgressBar": false,
            "classes": {
                "menu": "grey-color-font test",
                "hover": "dark-grey-color-font light-grey-color-bg",
                "progress": "b-blue-color-bg",
                "handle": "white-color-border"
            },
            "controls": {
                "menu": true,
                "prev": true,
                "next": true,
                "pause": false,
                "nextLabel": "NEXT"
            }
        },
        "autonext": {
            "enabled": false,
            "delay": 0
        },
        "reference": {
            "1": {
                "content": "OPDIVO [package insert]. Princeton, NJ: BristolMyers Squibb Company; 2018."
            },
            "2": {
                "content": "Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous <nobr>non-small-cell</nobr> lung cancer. <em>N Engl J Med.</em> <nobr>2015;373:1627-1639.</nobr>"
            },
            "3": {
                "content": "Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced <nobr>squamous-cell</nobr> <nobr>non-small-cell</nobr> lung cancer. <em>N Engl J Med.</em> <nobr>2015;373:123-135.</nobr>"
            },
            "4": {
                "content": "Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous <nobr>non-small-cell</nobr> lung cancer. <em>N Engl J Med.</em> <nobr>2015;373(17):1627-1639</nobr> <nobr>[supplementary appendix].</nobr>"
            },
            "5": {
                "content": "Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. <em>N Engl J Med.</em> <nobr>2015;373(2):123-125</nobr> <nobr>[supplementary appendix].</nobr>"
            },
            "6": {
                "content": "Long G, Tykodi S, Schneider J, et al. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer [published online ahead of print September&nbsp;12, 2018]. <em>Ann Oncol.</em> 2018; <nobr>doi.org/10.1093/annonc/mdy408.</nobr>"
            },
            "7": {
                "content": "Felip E, Gettinger S, Burgio MA, et al. Three-year <nobr>follow-up</nobr> from <nobr>CheckMate 017/057:</nobr> nivolumab versus docetaxel in patients with previously treated advanced <nobr>non-small</nobr> cell lung cancer. Poster presentation at ESMO 2017. Abstract 1301 PD"
            },
            "f1": {
                "content": "<img style='width:100%' src='https://c.mdchat-usa.com/programs/130201338/img/graph1.svg'/>"
            },
            "f2": {
                "content": "<img style='width:100%' src='https://c.mdchat-usa.com/programs/130201338/img/102.png'/>"
            },
            "f3": {
                "content": "<img style='width:100%' src='https://c.mdchat-usa.com/programs/130201338/img/103-1.svg'/>"
            },
            "f4": {
                "content": "<img style='width:100%' src='https://c.mdchat-usa.com/programs/130201338/img/201-1.svg'/>"
            },
            "f5": {
                "content": "<img style='width:100%' src='https://c.mdchat-usa.com/programs/130201338/img/202-1.svg'/>"
            },
            "f6": {
                "content": "<img style='width:100%' src='https://c.mdchat-usa.com/programs/130201338/img/301-1v2.png'/>"
            },
            "f7": {
                "content": "<img style='width:100%' src='https://c.mdchat-usa.com/programs/130201338/img/section1D-m.png'/>"
            },
            "f8": {
                "content": "<img style='width:100%' src='https://c.mdchat-usa.com/programs/130201338/img/section2c-m.png'/>"
            },
            "modalisi": {
                "content": "<h4 style='color: #024667;'>INDICATION</h4> <p>OPDIVO<sup>&reg;</sup> (nivolumab) is indicated for the treatment of patients with metastatic non&#8209;small cell lung cancer (NSCLC) with progression on or after platinum based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA&#8209;approved therapy for these aberrations prior to receiving OPDIVO.</p>"
            },
            "referenceAll": {
                "all": false
            }
        }
    },
    "pages": {
        "casey": {
            "use": [
                "page:default"
            ],
            "features": {
                "autonext": {
                    "disabled": true
                }
            },
            "sections": [
                {
                    "template": "MecBot",
                    "mecbotChat": {
                        "chat": [
                            {
                                "id": 0,
                                "answer": [
                                    "<img onload='$(&quot;#modalisi&quot;)[0].click();' class='avatar' style='width: 30px; position:absolute;' src='https://c.mdchat-usa.com/assets/images/edels/casey_1.gif'/><div style='margin-left:40px;'>Hello. I’m Casey. I’m here to help you discover why you should consider giving your patients with previously treated metastatic non-small cell lung cancer (mNSCLC) the OPDIVO<sup>&reg;</sup> (nivolumab) opportunity.</div>",
                                    "<p>Would you like to learn more about OPDIVO for patients with NSCLC with progression on or after <nobr>platinum-based</nobr> chemotherapy?",
                                    "OPDIVO is associated with the following Warnings and Precautions including immune-mediated: pneumonitis, colitis, hepatitis, endocrinopathies, nephritis and renal dysfunction, skin adverse reactions, encephalitis, other adverse reactions; infusion reactions; and embryo-fetal toxicity.</p><p style='margin-top:15px;'>Please see Important Safety Information below.</p>"
                                ],
                                "suggest": [
                                    1,
                                    2,
                                    4,
                                    3
                                ]
                            },
                            {
                                "id": 1,
                                "title": "Non-Squamous mNSCLC",
                                "objective": "1",
                                "prompt": [
                                    "I’d like to learn about the efficacy of OPDIVO<sup>&reg;</sup> in patients with previously treated <nobr>non-squamous mNSCLC.</nobr>"
                                ],
                                "answer": [
                                    "Before we review the clinical trial results, I’d like to share the Checkmate 057 study design with you.",
                                    "<p style='font-size: 12px !important;text-align: right;margin-bottom: 15px;'>Scroll down for more content</p> Checkmate 057 was a landmark, comparative study powered for survival. <reference id='1'>[ODIOVO PI]</reference> <reference id='3'>[Brahmer]</reference><div class='line'><div class='line-sect'><div style='position:relative;'><reference id='f1' style='position:absolute;width:100%;height:100%;'>&nbsp;</reference><img class='p-centerimg' style='width: 100%;' src='https://c.mdchat-usa.com/programs/130201338/img/graph1.svg'/></div></div><div class='line-sect' style='padding-right:20px;'><ul><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>Multinational, multicenter, <nobr>open-label,</nobr> randomized, phase 3 study that included <nobr>PD‑L1</nobr> expressors and <nobr>non-expressors</nobr></span></li><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>A prespecified analysis in this study evaluated subgroups defined by <nobr>PD‑L1</nobr> expression</span></li></ul><div style='transform:translate(12px);padding-left: 20px;'><div style='transform:translate(-12px, -3px);position:absolute;color:#f26322;'>&ndash;</div><p style='margin-bottom: 10px;'>In the evaluable patients (n=455), <nobr>PD‑L1</nobr> <nobr>non-expressors</nobr> were defined as &#60;1% of tumor cells expressing <nobr>PD‑L1 (n=209),</nobr> and <nobr>PD‑L1</nobr> expressors were defined as ≥1% of tumor cells expressing <nobr>PD-L1 (n=246)</nobr></p></div><div style='transform:translate(12px);padding-left: 20px;'><div style='transform:translate(-12px, -3px);position:absolute;color:#f26322;'>&ndash;</div><p style='margin-bottom: 10px;'>Patients in retrospectively determined subgroups were based on <nobr>PD-L1</nobr> testing using the <nobr>PD-L1</nobr> IHC <nobr>28-8</nobr> pharmDx assay</p><ul style='padding-left: 8px;'><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>Appropriate prior-targeted therapy in patients with known sensitizing EGFR mutation or ALK translocation was allowed</span></li><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>Patients with active autoimmune disease, including medical conditions requiring systemic immunosuppression, symptomatic interstitial lung disease, or untreated brain metastasis were excluded</span></li></ul><div style='margin-top: 15px;'><div style='position:absolute;transform:Translate(-7px, -1px);font-size:12px;'>*</div><p style='font-size:12px!important;'>The recommended dose of OPDIVO is either <nobr>240 mg</nobr> every <nobr>2 weeks</nobr> or <nobr>480 mg</nobr> every <nobr>4 weeks</nobr> administered as an intravenous infusion over <nobr>30 minutes</nobr> until disease progression or unacceptable toxicity. <reference id='1'>[OPDIVO PI]</reference><br><br>ALK=anaplastic lymphoma kinase; EGFR=epidermal growth factor receptor; IV=intravenous; <nobr>PD-L1</nobr>=programmed <nobr>death-ligand 1.</nobr></p></div></div></div>",
                                    "What efficacy topic would you like to explore in Checkmate 057 <nobr>non-squamous</nobr> mNSCLC?"
                                ],
                                "suggest": [
                                    102,
                                    103,
                                    104,
                                    105,
                                    100
                                ]
                            },
                            {
                                "id": 101,
                                "title": "ORR & mDOR",
                                "objective": "1",
                                "prompt": [
                                    "What was the objective response rate and median duration of response for <nobr>CHECKMATE 057?</nobr>"
                                ],
                                "answer": [
                                    "<ul><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>ORR with OPDIVO was 19% (56/292; 4 complete responses [95% CI: 15-24]) vs 12% with docetaxel (36/290; 1 complete response [95% CI: 9-17; <obr><em>P</em>=0.02]).</nobr> The median duration of response was <nobr>17 months</nobr> in the OPDIVO arm (95% CI: <nobr>8.4-NR)</nobr> and <nobr>6 months</nobr> in the docetaxel arm (95% CI: <nobr>4.4-7.0) <reference id='1'>[OPDIVO PI]</reference></nobr></span></li><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>HR for OS=0.73 (95% CI: 0.600.89; <em>P</em>=0.0015). Median OS was 12.2&nbsp;months (95% CI: 9.715.0) for OPDIVO and 9.4&nbsp;months (95% CI: 8.010.7) for docetaxel</span></li><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>Median PFS with OPDIVO was <nobr>2.3 months</nobr> vs <nobr>4.2 months</nobr> with docetaxel; HR=0.92, (95% CI: <nobr>0.77-1.11;</nobr> <nobr><em>P</em>=0.39) <reference id='1'>[OPDIVO PI]</reference></nobr></span></li></ul>"
                                ],
                                "suggest": [
                                    102,
                                    103,
                                    104,
                                    105,
                                    100
                                ]
                            },
                            {
                                "id": 102,
                                "title": "Clinical Trial Results: OS at <nobr>1 year</nobr>",
                                "objective": "1",
                                "prompt": [
                                    "What was the Overall Survival at <nobr>1 year</nobr> for patients with <nobr>non-squamous</nobr> mNSCLC treated with Opdivo vs. chemotherapy?"
                                ],
                                "answer": [
                                    "<p style='font-size: 12px !important;text-align: right;margin-bottom: 15px;'>Scroll down for more content</p><p style='margin-bottom:15px;'>In previously treated non-squamous NSCLC, OPDIVO achieved a significantly higher OS vs chemotherapy*, with over half of patients alive at 1 year (51% vs 39%). <reference id='1'>[ODIOVO PI]</reference> Also, OPDIVO demonstrated longer median OS of 17.1&nbsp;months vs 9.0&nbsp;months with chemotherapy* for patients expressing <nobr>PD-L1</nobr> at all levels (≥1%).<sup>&dagger;</sup></p> <div style='position:relative;'><reference id='f2' style='position:absolute;width:100%;height:100%;'>&nbsp;</reference><img style='width: 100%;' src='https://c.mdchat-usa.com/programs/130201338/img/102.png'/></div><br><ul><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>HR for OS=0.73 (95% CI: <nobr>0.60-0.89;</nobr> <em>P</em>=0.0015). Median OS was 12.2 months (95% CI: <nobr>9.7-15.0)</nobr> for OPDIVO and <nobr>9.4 months</nobr> (95% CI: <nobr>8.0-10.7)</nobr> for <nobr>docetaxel <reference id='1'>[OPDIVO PI]</reference></nobr></span></li><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>ORR with OPDIVO was 19% (56/292; 4 complete responses [95% CI: 15-24]) vs 12% with docetaxel (36/290; 1 complete response [95% CI: 9-17; <obr><em>P</em>=0.02]).</nobr> The median duration of response was <nobr>17 months</nobr> in the OPDIVO arm (95% CI: <nobr>8.4-NR)</nobr> and <nobr>6 months</nobr> in the docetaxel arm (95% CI: <nobr>4.4-7.0) <reference id='1'>[OPDIVO PI]</reference></nobr></span></li><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>Median PFS with OPDIVO was <nobr>2.3 months</nobr> vs <nobr>4.2 months</nobr> with docetaxel; HR=0.92, (95% CI: <nobr>0.77-1.11;</nobr> <nobr><em>P</em>=0.39) <reference id='1'>[OPDIVO PI]</reference></nobr></span></li><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>Checkmate 057 results were based on the prespecified interim analysis conducted when <nobr>413 events</nobr> (93% of the planned number of events for final analysis) were observed (190 in the OPDIVO arm and 223 in the docetaxel arm) <reference id='1'>[OPDIVO PI]</reference></span></li><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>OPDIVO reduced the risk of death by 41% in patients expressing PD-L1 at all levels (≥1%) (95% CI: 0.43-0.82)</span></li></ul><p style='font-size:12px!important'>*Docetaxel</p><div style='transform:translate(7px);margin-top:15px;'><div style='position:absolute;font-size:12px;transform:translate(-6px);'><sup>&dagger;</sup></div><p style='font-size: 12px!important;'>Median overall survival in patients treated with OPDIVO who had a PD-L1 expression level of ≥1%, ≥5%, or ≥10%.</p></div>",
                                    "What efficacy topic would you like to explore in Checkmate 057 <nobr>non-squamous</nobr> mNSCLC?"
                                ],
                                "suggest": [
                                    101,
                                    103,
                                    104,
                                    105,
                                    100
                                ]
                            },
                            {
                                "id": 103,
                                "title": "Overall Survival by PD-L1 Expression",
                                "objective": "1",
                                "prompt": [
                                    "What was the median overall survival based on <nobr>PD-L1</nobr> Expression for <nobr>CHECKMATE 057?</nobr>"
                                ],
                                "answer": [
                                    "<p style='font-size: 12px !important;text-align: right;margin-bottom: 15px;'>Scroll down for more content</p>OPDIVO<sup>&reg;</sup> demonstrated a longer median OS of <nobr>17.1 months</nobr> vs <nobr>9.0 months</nobr> with chemotherapy* for patients expressing <nobr>PD-L1</nobr> at all levels (1%). <reference id='1'>[ODIOVO PI]</reference><sup>&dagger;</sup> The median overall survival was based on prespecified analysis of <nobr>PD-L1</nobr> expression. <reference id='1'>[OPDIVO PI]</reference> <reference id='2'>[Borghaei]</reference> Let's have a look: <div style='position:relative;'><reference id='f3' style='position:absolute;width:100%;height:100%;'>&nbsp;</reference><img style='width: 100%;' src='https://c.mdchat-usa.com/programs/130201338/img/103-1.svg'/></div><br><p>Median overall survival (OS) vs chemotherapy* by <nobr>pre-specified</nobr> <nobr>PD-L1</nobr> expression level:</p><ul><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>&#60;5% (n=274): HR=1.01 (95% CI: 0.77–1.34); median OS=9.7 months with OPDIVO vs <nobr>10.1 months</nobr> with chemotherapy <reference id='1'>[OPDIVO PI]</reference> <reference id='2'>[Borghaei]</reference>*</span></li><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>&#60;10% (n=290): HR=1.00 (95% CI: 0.76–1.31); median <nobr>OS=9.9 months</nobr> with OPDIVO vs <nobr>10.3 months</nobr> with chemotherapy <reference id='1'>[OPDIVO PI]</reference> <reference id='2'>[Borghaei]</reference>*</span></li></ul><p style='font-size:12px!important;'>*Docetaxel</p><div style='transform:translate(7px)'><div style='transform:translate(-7px, -1px);font-size:12px;position:absolute;'><sup>&dagger;</sup></div><p style='font-size:12px!important;margin-bottom:5px;'><strong>Median overall survival in patients treated with OPDIVO who had a <nobr>PD-L1</nobr> expression level of ≥1%, ≥5%, or ≥10%.</strong></p></div><div style='transform:translate(7px)'><div style='transform:translate(-7px, -1px);font-size:12px;position:absolute;'><sup>&Dagger;</sup></div><p style='font-size:12px!important;margin-bottom:5px;'>Primary endpoint. All patients who underwent randomization were included in efficacy analysis (ITT=intent-to-treat-population).</p></div><div style='transform:translate(7px)'><div style='transform:translate(-7px, -1px);font-size:12px;position:absolute;'><sup>&sect;</sup></div><p style='font-size:12px!important;margin-bottom:5px;'>Based on a stratified proportional hazards model (HR=hazard ratio).</p></div><div style='transform:translate(7px)'><div style='transform:translate(-7px, -1px);font-size:12px;position:absolute;'><sup>||</sup></div><p style='font-size:12px!important;margin-bottom:5px;'>Based on a stratified <nobr>log-rank</nobr> test.</p></div><div style='transform:translate(7px)'><div style='transform:translate(-7px, -1px);font-size:12px;position:absolute;'><sup>&para;</sup></div><p style='font-size:12px!important;margin-bottom:5px;'><em>P</em>-value is compared with 0.0408 of the allocated alpha for this interim analysis.</p></div><div style='transform:translate(7px)'><div style='transform:translate(-7px, -1px);font-size:12px;position:absolute;position:absolute;'><sup>#</sup></div><p style='font-size:12px!important;margin-bottom:15px;'>78% of patients had quantifiable <nobr>PD-L1</nobr> expression (n=455/582). <nobr>PD-L1</nobr> non-expressors were defined as <1% of tumor cells expressing <nobr>PD-L1</nobr> (n=209) and <nobr>PD-L1</nobr> expressors were defined as ≥1% of tumor cells expressing <nobr>PD-L1</nobr> (n=246).</p><p style='font-size:12px!important;margin-bottom:5px;'>PD-L1=programmed <nobr>death-ligand 1.</nobr></p></div>",
                                    "What efficacy topic would you like to explore?"
                                ],
                                "suggest": [
                                    102,
                                    104,
                                    105,
                                    100
                                ]
                            },
                            {
                                "id": 104,
                                "title": "3 Year OS",
                                "objective": "1",
                                "prompt": [
                                    "What were the 3 years overall survival rates (from an  exploratory extended <nobr>follow-up</nobr> analysis) for <nobr>Checkmate 057?</nobr>"
                                ],
                                "answer": [
                                    "<p style='font-size: 12px !important;text-align: right;margin-bottom: 15px;'>Scroll down for more content</p>Of course. For previously treated metastatic <nobr>non-squamous NSCLC</nobr>, OPDIVO<sup>&reg;</sup> achieved a significantly higher OS vs chemotherapy,* with over half of patients alive at <nobr>1 Year</nobr> (51% vs 39%). <reference id='1'>[ODIOVO PI]</reference> <reference id='2'>[Borghaei]</reference></p><div style='position:relative;margin-top:15px;margin-bottom:15px;'><reference id='f7' style='position:absolute;width:100%;height:100%;'>&nbsp;</reference><img style='width: 100%;' src='https://c.mdchat-usa.com/programs/130201338/img/section1D-m.png'/></div><p style='font-size:12px!important;margin-bottom:15px;'>*Docetaxel</p><p style='font-size:12px!important;'>Data shown here are from all the patients who underwent randomization and were included in efficacy analysis (intent-to-treat population).<br>Refer to Overall Survival Figure for Metastatic Non-small Cell Lung Cancer in the <a href='http://packageinserts.bms.com/pi/pi_opdivo.pdf' target='_blank' style='font-weight:bold;color:#003B5C;'>Full Prescribing Information</a> for data on censored patients.<br><br>CI=confidence interval; HR=hazard ratio; NR=not reached; NSCLC=non-small cell lung cancer; ORR=overall response rate; OS=overall survival; PFS=profession-free survival.</p><ul style='margin-top:15px;'><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>ORR with OPDIVO was 19% (56/292; 4 complete responses) [95% CI: 15-24] vs 12% (36/290; 1 complete response) with docetaxel <nobr>[95% CI-9-17]</nobr> <nobr>(<em>P</em>=0.02).</nobr> The median duration of response was <nobr>17 months</nobr> with OPDIVO [95% CI: <nobr>8.4-NR]</nobr> and <nobr>6 months</nobr> in the docetaxel arm [95% CI: <nobr>4.4-7.0]</nobr></span></li><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>Median PFS with OPDIVO was 2.3 months vs 4.2 months with docetaxel; HR=0.92 (95% CI: 0.77-1.11) <nobr><em>P</em>=0.39</nobr></span></li><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>Checkmate 057 results were based on the pre-specified interim analysis conducted when <nobr>413 events</nobr> (93% of the planned number of events for final analysis) were observed (190 in the OPDIVO arm and 223 in the docetaxel arm)</span></li></ul>",
                                    "What efficacy topic would you like to explore?"
                                ],
                                "suggest": [
                                    102,
                                    103,
                                    105,
                                    100
                                ]
                            },
                            {
                                "id": 105,
                                "title": "Baseline Characteristics",
                                "objective": "1",
                                "prompt": [
                                    "What where the baseline characteristics for patients enrolled in CHECKMATE 057?"
                                ],
                                "answer": [
                                    "<p style='font-size: 12px !important;text-align: right;margin-bottom: 15px;'>Scroll down for more content</p>Sure. OPDIVO was evaluated in a comparative trial, <reference id='2'>[Borghaei]</reference> <reference id='4'>[Borghaei Suppl]</reference> and patient baseline characteristics were:</p><table class='table-105' style='border-collapse: inherit;'><tr><th style='border-bottom:1px solid #dadada;background-color:white;'></th><th style='background-color:#009ABD;border-bottom:1px solid #dadada;'>OPDIVO<br>(n=292)</th><th style='background-color:#999999;border-bottom:1px solid #dadada;border-top-right-radius:5px;'>DOCETAXEL<br>(n=290)</th></tr><tr><td style='border-bottom:1px solid #dadada;'><strong>Median Age Years (Range) <nobr>≥75 years</nobr></strong></td><td style='border-bottom:1px solid #dadada;'><strong>61<br>(37-84)<br>7%</strong></td><td style='border-bottom:1px solid #dadada;'><strong>64<br>(21-85)<br>8%</strong></td></tr><tr><td style='border-bottom:1px solid #dadada;'><strong>Male</strong></td><td style='border-bottom:1px solid #dadada;'><strong>52%</strong></td><td style='border-bottom:1px solid #dadada;'><strong>58%</strong></td></tr><tr><td><strong>Smoking Status</strong></td><td></td><td></td></tr><tr><td>Current/former smoker</td><td><strong>79%</strong></td><td><strong>78%</strong></td></tr><tr><td style='border-bottom:1px solid #dadada;'>Never smoker</td><td style='border-bottom:1px solid #dadada;'><strong>20%</strong></td><td style='border-bottom:1px solid #dadada;'><strong>21%</strong></td></tr><tr><td><strong>ECOG Performance Status*</strong></td><td></td><td></td></tr><tr><td>0</td><td><strong>29%</strong></td><td><strong>33%</strong></td></tr><tr><td style='border-bottom:1px solid #dadada;'>1</td><td style='border-bottom:1px solid #dadada;'><strong>71%</strong></td><td style='border-bottom:1px solid #dadada;'><strong>67%</strong></td></tr><tr><td style='border-bottom:1px solid #dadada;'><strong>Prior Maintenance Therapy</strong></td><td style='border-bottom:1px solid #dadada;'>42%</td><td style='border-bottom:1px solid #dadada;'>38%</td></tr><tr><td><strong>Number of Prior Systemic Regimens<sup>†‡</sup></strong></td><td></td><td></td></tr><tr><td>1</td><td><strong>88%</strong></td><td><strong>89%</strong></td></tr><tr><td style='border-bottom:1px solid #dadada;'>2</td><td style='border-bottom:1px solid #dadada;'><strong>12%</strong></td><td style='border-bottom:1px solid #dadada;'><strong>11%</strong></td></tr><tr><td style='border-bottom:1px solid #dadada;'><strong><em>EGFR</em>-Positive Mutation Status</strong></td><td style='border-bottom:1px solid #dadada;'><strong>15%</strong></td><td style='border-bottom:1px solid #dadada;'><strong>13%</strong></td></tr><tr><td style='border-bottom-left-radius:7px;'><strong><em>ALK</em>-Positive Translocation Status</strong></td><td><strong>4%</strong></td><td style='border-bottom-right-radius:5px;'><strong>3%</strong></td></tr></table><p style='font-size:12px!important;margin-bottom:5px;margin-top:15px;'><span style='display: inline-block;text-indent: -5px;'>*</span>One patient in the docetaxel arm had ECOG Performance Status of 3.</p><p style='font-size:12px!important;margin-bottom:5px;'><span style='display: inline-block;text-indent: -5px;'><sup>&dagger;</sup></span>Derived as number of lines of prior therapy received for advanced, metastatic, or recurrent disease.</p><p style='font-size:12px!important;margin-bottom:5px;'><span style='display: inline-block;text-indent: -5px;'><sup>&Dagger;</sup></span>One patient had 1 prior regimen in the neoadjuvant setting.</p><p style='font-size:12px!important;'>ALK=anaplastic lymphoma kinase;      ECOG=Eastern Cooperative Oncology Group; EGFR=epidermal growth factor receptor.</p>"
                                ],
                                "suggest": [
                                    102,
                                    103,
                                    104,
                                    100
                                ]
                            },
                            {
                                "id": 200,
                                "title": "Something Else",
                                "objective": "2",
                                "prompt": [
                                    "I'd like to see another topic."
                                ],
                                "answer": [
                                    "Would you like to learn more about OPDIVO in patients with previously treated mNSCLC."
                                ],
                                "suggest": [
                                    1,
                                    2,
                                    4,
                                    3,
                                    600,
                                    700
                                ]
                            },
                            {
                                "id": 2,
                                "title": "Squamous mNSCLC",
                                "objective": "2",
                                "prompt": [
                                    "I’d like to learn about the efficacy of OPDIVO in patients with previously treated <nobr>squamous mNSCLC.</nobr>"
                                ],
                                "answer": [
                                    "<p style='font-size: 12px !important;text-align: right;margin-bottom: 15px;'>Scroll down for more content</p>Checkmark 017 was a landmark, Phase 3 study powered for survival. <reference id='1'>[ODIOVO PI]</reference><reference id='3'>[Brahmer]</reference><div class='line'><div class='line-sect'><div style='position:relative;'><reference id='f4' style='position:absolute;width:100%;height:100%;'>&nbsp;</reference><img class='p-centerimg' style='width: 100%;' src='https://c.mdchat-usa.com/programs/130201338/img/201-1.svg'/></div></div><div class='line-sect' style='padding-right:20px;'><ul><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>Multinational, multicenter, <nobr>open-label,</nobr> randomized, phase <nobr>3 study</nobr></span></li><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>Study included patients regardless of <nobr>PD-L1 status</nobr></span></li></ul><div style='transform:translate(12px);padding-left: 20px;'><div style='transform:translate(-12px, -3px);position:absolute;color:#f26322;'>&ndash;</div><p style='margin-bottom: 10px;'>Archival tumor specimens were retrospectively evaluated for <nobr>PD-L1</nobr> expression. Across the study population, 17% (47/272) of patients had <nobr>non-quantifiable</nobr> results. Among the <nobr>225 patients</nobr> with quantifiable results, 47% (106/225) had <nobr>PD-L1–negative</nobr> squamous NSCLC, defined as &#60;1% of tumor cells expressing <nobr>PD-L1,</nobr> and 53% (119/225) had <nobr>PD-L1–positive</nobr> squamous NSCLC, defined as ≥1% of tumor cells expressing <nobr>PD-L1</nobr></p></div><ul style='padding-left: 40px;'><li style='color:#f26322;margin-bottom: 10px;margin-left: 0px;'><span style='color:#666;'>The trial excluded patients with autoimmune disease, medical conditions requiring systemic immunosuppression, symptomatic interstitial lung disease, or untreated brain metastasis</span></li></ul><div style='margin-top: 15px;margin-left:30px;'><div style='position:absolute;transform:Translate(-7px, -1px);font-size:12px;'>*</div><p style='font-size:12px!important;'>The recommended dose of OPDIVO is either <nobr>240 mg</nobr> every <nobr>2 weeks</nobr> or <nobr>480 mg</nobr> every <nobr>4 weeks</nobr> administered as an intravenous infusion over <nobr>30 minutes</nobr> until disease progression or unacceptable toxicity.<br><br>IV=intravenous; NR=not reached; <nobr>PD-L1=programmed</nobr> <nobr>death-ligand 1.</nobr></p></div></div></div>",
                                    "What efficacy topic would you like to explore in <nobr>Checkmate 017</nobr> squamous mNSCLC?"
                                ],
                                "suggest": [
                                    202,
                                    203,
                                    204,
                                    200
                                ]
                            },
                            {
                                "id": 201,
                                "title": "ORR & mDOR",
                                "objective": "2",
                                "prompt": [
                                    ""
                                ],
                                "answer": [
                                    "<ul><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>ORR with OPDIVO was 20% (27/135; 1 complete response) [95% CI:14-28] vs 9% (12/137; 0 complete response) with docetaxel [95% CI; 5-15] (<em>P</em>=0.0083). The median duration of response was NR with OPDIVO [95% CI: 9.8-NR] and <nobr>8.4 months</nobr> in the docetaxel arm [95% CI: <nobr>3.6-10.80</nobr></span></li><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>HR for OS=0.73 (95% CI: 0.600.89; <em>P</em>=0.0015). Median OS was 12.2&nbsp;months (95% CI: 9.715.0) for OPDIVO and 9.4&nbsp;months (95% CI: 8.010.7) for docetaxel</span></li><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>Median PFS with OPDIVO was <nobr>3.5 months</nobr> vs <nobr>2.8 months</nobr> with docetaxel; HR=0.62 [95% CI: 0.47-0.81], <nobr><em>P</em>=0.0004</nobr></span></li></ul>"
                                ],
                                "suggest": [
                                    202,
                                    203,
                                    204,
                                    200
                                ]
                            },
                            {
                                "id": 202,
                                "title": "Overall Survival (OS) at 1 year",
                                "objective": "2",
                                "prompt": [
                                    "What was the overall survival?"
                                ],
                                "answer": [
                                    "<p style='font-size: 12px !important;text-align: right;margin-bottom: 15px;'>Scroll down for more content</p>For previously treated metastatic <nobr>squamous NSCLC</nobr> regardless of <nobr>PD-L1</nobr> expression</strong>, OPDIVO<sup>&reg;</sup> delivered 50% longer mOS vs chemotherapy* (9.2 vs <nobr>6.0 months),</nobr> in a study designed to include <nobr>PD-L1</nobr> expressors and <nobr>non-expressors. <reference id='3'>[Brahmer]</reference></nobr> Here's Checkmate 017 overall survival data. <reference id='1'>[OPDIVO PI]</reference> <reference id='3'>[Brahmer]</reference><p style='font-size:12px!important;margin-bottom:15px;'>*Docetaxel.</p><div style='position:relative;text-align: center;margin-bottom: 15px;'><reference id='f5' style='position:absolute;width:100%;height:100%;'>&nbsp;</reference><img style='width: 100%;max-width:550px;' src='https://c.mdchat-usa.com/programs/130201338/img/202-1.svg'/></div><p style='font-size:12px!important;margin-bottom:5px;'>Refer to Overall Survival Figure for Metastatic <nobr>Non-Small</nobr> Cell Lung Cancer in the <a href='http://packageinserts.bms.com/pi/pi_opdivo.pdf' style='color:#009ABD;' target='_blank'>Full Prescribing Information</a> for data on censored patients.</p><p style='font-size:12px!important;margin-bottom:5px;'>CI=confidence interval; HR=hazard ratio; mNSCLC=metastatic <nobr>non-small</nobr> cell lung cancer; mOS=median overall survival; <nobr>PD-L1=programmed</nobr> <nobr>death-ligand 1.</nobr></p>"
                                ],
                                "suggest": [
                                    201,
                                    203,
                                    204,
                                    200
                                ]
                            },
                            {
                                "id": 203,
                                "title": "3 Year Overall Survival",
                                "objective": "2",
                                "prompt": [
                                    "What were the 3 years overall survival rates (from an exploratory extended <nobr>follow-up</nobr> analysis) for <nobr>Checkmate 017?</nobr>"
                                ],
                                "answer": [
                                    "<p style='font-size: 12px !important;text-align: right;margin-bottom: 15px;'>Scroll down for more content</p>No problem. For previously treated metastatic <nobr>squamous NSCLC</nobr></strong>, OPDIVO<sup>&reg;</sup> delivered 50% longer mOS vs chemotherapy* (9.2 vs <nobr>6.0 months),</nobr> in a study designed to include <nobr>PD-L1</nobr> expressors and <nobr>non-expressors <reference id='1'>[ODIOVO PI]</reference></nobr></p><div style='position:relative;margin-top:15px;margin-bottom:15px;'><reference id='f8' style='position:absolute;width:100%;height:100%;'>&nbsp;</reference><img style='width: 100%;' src='https://c.mdchat-usa.com/programs/130201338/img/section2c-m.png'/></div><p style='margin-bottom:15px;font-size:12px!important;'>Refer to Overall Survival Figure for Metastatic <nobr>Non-Small</nobr> Cell Lung Cancer in the <a <a href='http://packageinserts.bms.com/pi/pi_opdivo.pdf' target='_blank' style='font-weight:bold;color:#003B5C;'>Full Prescribing Information</a> for data on censored patients.</p><p style='font-size:12px!important;margin-bottom:15px;'>*Docetaxel</p><p style='font-size:12px!important;margin-bottom:15px;'>CI=confidence interval; HR=hazard ratio; NR=not reached; NSCLC=non-small cell lung cancer; ORR=overall response rate; OS=overall survival; PFS=profession-free survival.</p><ul><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>ORR with OPDIVO was 20% (27/135; 1 complete response) [95% CI:14-28] vs 9% (12/137; 0 complete response) with docetaxel [95% CI; 5-15] (<em>P</em>=0.0083). The median duration of response was NR with OPDIVO [95% CI: 9.8-NR] and <nobr>8.4 months</nobr> in the docetaxel arm [95% CI: <nobr>3.6-10.80</nobr></span></li><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>Median PFS with OPDIVO was <nobr>3.5 months</nobr> vs <nobr>2.8 months</nobr> with docetaxel; HR=0.62 [95% CI: 0.47-0.81], <nobr><em>P</em>=0.0004</nobr></span></li><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>OPDIVO demonstrated a 41% reduction in the risk of death compared with docetaxel</span></li><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>Results were based on the pre-specified interim analysis conducted when 199 events (86% of the planned number of events for final analysis) were observed (86 in the OPDIVO arm and 113 in the docetaxel arm)</span></li></ul>",
                                    "OPDIVO<sup>&reg;</sup> is the first and only <nobr>PD-1</nobr> Inhibitor to nearly double <nobr>1-year</nobr> overall survival rate vs chemotherapy <reference id='1'>[OPDIVO PI]</reference> <reference id='7'>[Felip]</reference></strong>",
                                    "What other topic would you like to explore regarding OPDIVO in patients with previously treated mNSCLC?"
                                ],
                                "suggest": [
                                    201,
                                    202,
                                    204,
                                    200
                                ]
                            },
                            {
                                "id": 204,
                                "title": "Baseline characteristic",
                                "objective": "2",
                                "prompt": [
                                    "What were the Checkmate 017 baseline patient characteristics?"
                                ],
                                "answer": [
                                    "<p style='font-size: 12px !important;text-align: right;margin-bottom: 15px;'>Scroll down for more content</p>Sure. OPDIVO<sup>&reg;</sup> was evaluated in a comparative trial, <reference id='2'>[Borghaei]</reference> <reference id='4'>[Borghaei Suppl]</reference> and the patient baseline characteristics were:<br><table class='table-105' style='border-collapse: inherit;margin-top:15px;'><tr><th style='border-bottom:1px solid #dadada;background-color:white;'></th> <th style='background-color:#009ABD;border-bottom:1px solid #dadada;'>OPDIVO <br>(n=135)</th><th style='background-color:#999999;border-bottom:1px solid #dadada;border-top-right-radius:5px;'>DOCETAXEL <br>(n=137)</th></tr><tr><td style='border-bottom:1px solid #dadada;'><strong>Median Age Years (Range)</strong></td> <td style='border-bottom:1px solid #dadada;'><strong>62 (39-85)</strong></td><td style='border-bottom:1px solid #dadada;'><strong>64 (42-84)</strong></td></tr><tr><td><strong>Gender</strong></td><td></td><td></td></tr><tr><td>Male</td><td><strong>82%</strong></td><td><strong>71%</strong></td></tr><tr><td style='border-bottom:1px solid #dadada;'>Female</td><td style='border-bottom:1px solid #dadada;'><strong>18%</strong></td><td style='border-bottom:1px solid #dadada;'><strong>29%</strong></td></tr><tr><td><strong>Race</strong></td><td></td><td></td></tr><tr><td style='border-bottom:1px solid #dadada;'>white</td><td style='border-bottom:1px solid #dadada;'><strong>90%</strong></td><td style='border-bottom:1px solid #dadada;'><strong>95%</strong></td></tr><tr><td><strong>Stage of Disease*</strong></td><td></td><td></td></tr><tr><td>IIIB</td><td><strong>21%</strong></td><td><strong>82%</strong></td></tr><tr><td style='border-bottom:1px solid #dadada;'>IV</td><td style='border-bottom:1px solid #dadada;'><strong>78%</strong></td><td style='border-bottom:1px solid #dadada;'><strong>82%</strong></td></tr><tr><td><strong>Stage of Disease</strong></td><td></td><td></td></tr><tr><td>IIIB</td><td><strong>21%</strong></td><td><strong>82%</strong></td></tr><tr><td style='border-bottom:1px solid #dadada;'>IV</td><td style='border-bottom:1px solid #dadada;'><strong>78%</strong></td><td style='border-bottom:1px solid #dadada;'><strong>82%</strong></td></tr><tr><td><strong>ECOG Performance Status</strong></td><td></td><td></td></tr><tr><td>0</td><td><strong>20%</strong></td><td><strong>27%</strong></td></tr><tr><td style='border-bottom:1px solid #dadada;'>1</td><td style='border-bottom:1px solid #dadada;'><strong>79%</strong></td><td style='border-bottom:1px solid #dadada;'><strong>73%</strong></td></tr><tr><td><strong>Number of Prior Treatments</strong></td><td></td><td></td></tr><tr><td>1</td><td><strong>99%</strong></td><td><strong>100%</strong></td></tr><tr><td style='border-bottom:1px solid #dadada;border-bottom-left-radius:5px;'>2</td><td style='border-bottom:1px solid #dadada;'><strong>1%</strong></td><td style='border-bottom:1px solid #dadada;border-bottom-right-radius:5px;'><strong>0%</strong></td></tr></table><div style='transform:translate(7px);margin-top:15px;'><div style='position:absolute;font-size:12px;transform:translate(-6px);'>*</div><p style='font-size: 12px!important;'>Patients were staged according to version 7 of the International Association of the Study of Lung Cancer manual in Thoracic Oncology</p></div><p style='font-size:12px!important;margin-top:15px;'>ECOG=Eastern Cooperative Oncology Group.</p>"
                                ],
                                "suggest": [
                                    201,
                                    202,
                                    203,
                                    200
                                ]
                            },
                            {
                                "id": 3,
                                "title": "Dosing and Administration",
                                "objective": "3",
                                "prompt": [
                                    "How do I dose patients with previously treated mNSCLC with OPDIVO?"
                                ],
                                "answer": [
                                    "<p style='font-size: 12px !important;text-align: right;margin-bottom: 15px;'>Scroll down for more content</p>With a q4W (480-mg) dosing option, OPDIVO<sup>&reg;</sup> is the only <nobr>immuno-oncology</nobr> therapy with flexible dosing schedules to help meet the needs of your patients. <reference id='1'>[OPDIVO PI]</reference> <reference id='6'>[Long]</reference></strong> You can customize patients management with the choice of <nobr>2 dosing options</nobr>:<br><div style='position:relative;text-align:center;margin-bottom:15px;margin-top:12px;'><reference id='f6' style='position:absolute;width:100%;height:100%;'>&nbsp;</reference><img style='width: 100%;max-width:500px;' src='https://c.mdchat-usa.com/programs/130201338/img/301-1v2.png'/></div><ul><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>Based on exploratory dose exposure response relationships for efficacy and safety, OPDIVO <nobr>q2w 240 mg</nobr> and <nobr>q4w 480 mg</nobr> are predicted to be <nobr>similar <reference id='6'>[Long]</reference></nobr></span></li><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>No premedication required</span></li><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>Dose until disease progression or unacceptable toxicity</span></li><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>240-mg/24-mL vial available</span></li></ul><div style='text-align:center;margin-bottom:15px;'><img src='https://c.mdchat-usa.com/programs/130201338/img/301-2.svg' style='max-width:150px;'></div><p style='font-size:12px!important;'>IV=intravenous; q2w=every 2 weeks; q4w=every <nobr>4 weeks.</nobr></p>"
                                ],
                                "suggest": [
                                    302,
                                    300
                                ]
                            },
                            {
                                "id": 300,
                                "title": "Something Else",
                                "objective": "3",
                                "prompt": [
                                    "I'd like to see another topic."
                                ],
                                "answer": [
                                    "Would you like to learn more about OPDIVO in patients with previously treated mNSCLC."
                                ],
                                "suggest": [
                                    1,
                                    2,
                                    3,
                                    4,
                                    600,
                                    700
                                ]
                            },
                            {
                                "id": 302,
                                "title": "Treatment Modifications",
                                "objective": "3",
                                "prompt": [
                                    "How do I modify the dosing of OPDIVO to manage adverse reactions?"
                                ],
                                "answer": [
                                    "All right. It’s helpful to know that adverse reactions may be managed with treatment modifications. <reference id='1'>[OPDIVO PI]</reference> Which of the following adverse reactions do you see the recommended dose modifications for <nobr>OPDIVO<sup>&reg;</sup>?</nobr>"
                                ],
                                "suggest": [
                                    303,
                                    304,
                                    305,
                                    306,
                                    300
                                ]
                            },
                            {
                                "id": 303,
                                "title": "Colitis, Pneumonitis &amp; Hepatitis",
                                "objective": "3",
                                "prompt": [
                                    "What are the recommended dose modifications for OPDIVO<sup>&reg;</sup> for colitis, pneumonitis and hepatitis?"
                                ],
                                "answer": [
                                    "<p style='font-size: 12px !important;text-align: right;margin-bottom: 15px;'>Scroll down for more content</p>See the chart below:<br><table class='table-303' style='border-collapse: inherit;margin-top:15px;'><tr><td colspan='2' class='header' style='border-top-left-radius:8px;border-top-right-radius:8px;'><strong>Colitis</strong></td><tr><tr><td class='b-header'> Severity* </td><td class='b-header'> Dose Modification </td></tr><tr><td class='t-content'>Grade 2 diarrhea or colitis</td><td class='t-content'>Withhold dose<sup>&dagger;</sup></td></tr><tr><td class='t-content'>Grade 3 diarrhea or colitis</td><td class='t-content'>Withhold dose<sup>&dagger;</sup></td></tr><tr><td class='t-content'>Grade 4 diarrhea or colitis</td><td class='t-content'>Permanently discontinue</td></tr><tr><td colspan='2' class='header'><strong>Pneumonitis</strong></td><tr><tr><td class='b-header'> Severity* </td><td class='b-header'> Dose Modification </td></tr><tr><td class='t-content'>Grade 2 pneumonitis</td><td class='t-content'>Withhold dose<sup>&dagger;</sup></td></tr><tr><td class='t-content'>Grade 3 or 4 pneumonitis</td><td class='t-content'>Permanently discontinue</td></tr><tr><td colspan='2' class='header'><strong>Hepatitis</strong></td><tr><tr><td class='b-header'> Severity* </td><td class='b-header'> Dose Modification </td></tr><tr><td class='t-content'><ul style='padding-left:38px;margin-top:0;'><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>AST or ALT &#62;3 and ≤5x the ULN or total bilirubin &#62;1.5 and ≤3x the ULN</span></li></ul></td><td class='t-content'>Withhold dose<sup>&dagger;</sup></td></tr><tr><td class='t-content' style='border-bottom-left-radius:5px;'><ul style='padding-left:38px;margin-top:0;'><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>AST or ALT &#62;5x the ULN or total bilirubin &#62;3x the ULN</span></li></ul></td><td class='t-content' style='border-bottom-right-radius:5px;'>Permanently discontinue</td></tr><tr></table><p style='font-size:12px!important;margin-bottom:5px;margin-top:15px;'><span style='display: inline-block;text-indent: -5px;'>*</span>Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events. <nobr>(NCI CTCAE) v4.0.</nobr></p><p style='font-size:12px!important;margin-bottom:10px;'><span style='display: inline-block;text-indent: -5px;'><sup>&dagger;</sup></span>Resume treatment when adverse reaction improves to Grade <nobr>0 or 1.</nobr></p><p style='font-size:12px!important;'>ALT=alanine aminotransferase; AST=aspartate aminotransferase; SJS=Stevens-Johnson syndrome; TEN=toxic epidermal necrolysis; ULN=upper limit of normal.</p>",
                                    "What other adverse reactions do you want to see the recommended dose modifications for <nobr>OPDIVO<sup>&reg;</sup>?</nobr>"
                                ],
                                "suggest": [
                                    304,
                                    305,
                                    306,
                                    300
                                ]
                            },
                            {
                                "id": 304,
                                "title": "Hypophysitis, Adrenal Insufficiency &amp; Type 1 DM",
                                "objective": "3",
                                "prompt": [
                                    "What are the recommended dose modifications for OPDIVO<sup>&reg;</sup> for hypophysitis, adrenal insufficiency and Type 1 Diabetes Mellitus?"
                                ],
                                "answer": [
                                    "<p style='font-size: 12px !important;text-align: right;margin-bottom: 15px;'>Scroll down for more content</p>Sure.  See the chart below:<br><table class='table-303' style='border-collapse: inherit;margin-top:15px;'><tr><td colspan='2' class='header' style='border-top-left-radius:8px;border-top-right-radius:8px;'><strong>Hypophysitis</strong></td><tr><tr><td class='b-header'> Severity* </td><td class='b-header'> Dose Modification </td></tr><tr><td class='t-content'>Grade 2 or 3 hypophysitis</td><td class='t-content'>Withhold dose<sup>&dagger;</sup></td></tr><tr><td class='t-content'>Grade 4 hypophysitis</td><td class='t-content'>Permanently discontinue</td></tr><tr><td colspan='2' class='header'><strong>Adrenal Insufficiency</strong></td><tr><tr><td class='b-header'> Severity* </td><td class='b-header'> Dose Modification </td></tr><tr><td class='t-content'>Grade 2 adrenal insufficiency</td><td class='t-content'>Withhold dose<sup>&dagger;</sup></td></tr><tr><td class='t-content'>Grade 3 or 4 adrenal insufficiency</td><td class='t-content'>Permanently discontinue</td></tr><tr><td colspan='2' class='header'><strong>Type 1 Diabetes Mellitus</strong></td><tr><tr><td class='b-header'> Severity* </td><td class='b-header'> Dose Modification </td></tr><tr><td class='t-content'>Grade 3 hyperglycemia</td><td class='t-content'>Withhold dose<sup>&dagger;</sup></td></tr><tr><td class='t-content' style='border-bottom-left-radius:5px;'>Grade 4 hyperglycemia</td><td class='t-content' style='border-bottom-right-radius:5px;'>Permanently discontinue</td></tr><tr></table><p style='font-size:12px!important;margin-bottom:5px;margin-top:15px;'><span style='display: inline-block;text-indent: -5px;'>*</span>Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events. <nobr>(NCI CTCAE) v4.0.</nobr></p><p style='font-size:12px!important;margin-bottom:10px;'><span style='display: inline-block;text-indent: -5px;'><sup>&dagger;</sup></span>Resume treatment when adverse reaction improves to Grade <nobr>0 or 1.</nobr></p><p style='font-size:12px!important;'>ALT=alanine aminotransferase; AST=aspartate aminotransferase; SJS=Stevens-Johnson syndrome; TEN=toxic epidermal necrolysis; ULN=upper limit of normal.</p>",
                                    "What other adverse reactions do you want to see the recommended dose modifications for <nobr>OPDIVO<sup>&reg;</sup>?</nobr>"
                                ],
                                "suggest": [
                                    303,
                                    305,
                                    306,
                                    300
                                ]
                            },
                            {
                                "id": 305,
                                "title": "Nephritis, Renal Dysfunction &amp; Skin",
                                "objective": "3",
                                "prompt": [
                                    "What are the recommended dose modifications for OPDIVO<sup>&reg;</sup> for nephritis, renal dysfunction and skin reactions?"
                                ],
                                "answer": [
                                    "<p style='font-size: 12px !important;text-align: right;margin-bottom: 15px;'>Scroll down for more content</p>See the chart below:<br><table class='table-303' style='border-collapse:inherit;margin-top:15px;'><tr><td colspan='2' class='header' style='border-top-left-radius:8px;border-top-right-radius:8px;'><strong>Nephritis and Renal Dysfunction</strong></td><tr><tr><td class='b-header'> Severity* </td><td class='b-header'> Dose Modification </td></tr><tr><td class='t-content'>Serum creatinine &#62;1.5 and ≤6x the ULN</td><td class='t-content'>Withhold dose<sup>&dagger;</sup></td></tr><tr><td class='t-content'>Serum creatinine &#62;6x the ULN</td><td class='t-content'>Permanently discontinue</td></tr><tr><td colspan='2' class='header'><strong>Skin</strong></td><tr><tr><td class='b-header'> Severity* </td><td class='b-header'> Dose Modification </td></tr><tr><td class='t-content'>Grade 3 rash or suspected SJS orTEN</td><td class='t-content'>Withhold dose<sup>&dagger;</sup></td></tr><tr><td class='t-content' style='border-bottom-left-radius:5px;'>Grade 4 rash or confirmed SJS orTEN</td><td class='t-content' style='border-bottom-right-radius:5px;'>Permanently discontinue</td></tr></table><p style='font-size:12px!important;margin-bottom:5px;margin-top:15px;'><span style='display: inline-block;text-indent: -5px;'>*</span>Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events. <nobr>(NCI CTCAE) v4.0.</nobr></p><p style='font-size:12px!important;margin-bottom:10px;'><span style='display: inline-block;text-indent: -5px;'><sup>&dagger;</sup></span>Resume treatment when adverse reaction improves to Grade <nobr>0 or 1.</nobr></p><p style='font-size:12px!important;'>ALT=alanine aminotransferase; AST=aspartate aminotransferase; SJS=Stevens-Johnson syndrome; TEN=toxic epidermal necrolysis; ULN=upper limit of normal.</p>",
                                    "What other adverse reactions do you want to see the recommended dose modifications for <nobr>OPDIVO<sup>&reg;</sup>?</nobr>"
                                ],
                                "suggest": [
                                    303,
                                    304,
                                    306,
                                    300
                                ]
                            },
                            {
                                "id": 306,
                                "title": "Encephalitis &amp; Other Adverse Events",
                                "objective": "3",
                                "prompt": [
                                    "What are the recommended dose modifications for OPDIVO<sup>&reg;</sup> for encephalitis and other adverse events?"
                                ],
                                "answer": [
                                    "<p style='font-size: 12px !important;text-align: right;margin-bottom: 15px;'>Scroll down for more content</p>Have a look at the chart below:<br><table class='table-303' style='border-collapse:inherit;margin-top:15px;'><tr><td colspan='2' class='header' style='border-top-left-radius:8px;border-top-right-radius:8px;'><strong>Encephalitis</strong></td><tr><tr><td class='b-header'> Severity* </td><td class='b-header'> Dose Modification </td></tr><tr><td class='t-content'>New-onset of moderate or severe neurologic signs or symptoms</td><td class='t-content'>Withhold dose<sup>&dagger;</sup></td></tr><tr><td class='t-content'>Immune-mediated encephalitis</td><td class='t-content'>Permanently discontinue</td></tr><tr><td colspan='2' class='header'><strong>Other</strong></td><tr><tr><td class='b-header'> Severity* </td><td class='b-header'> Dose Modification </td></tr><tr><td class='t-content'>Other Grade 3 adverse reaction<ul style='padding-left:38px;margin-top:0;margin-bottom:0;'><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>First occurrence</span></li><li style='color:#f26322;margin-bottom: 0px;'><span style='color:#666;'>Recurrence of same Grade 3 adverse reactions</span></li></ul></td><td class='t-content'>Withhold dose<sup>&dagger;</sup><br><br>Permanently discontinue</td></tr><tr><td class='t-content' style='border-bottom-left-radius:5px;'>Life-threatening or Grade 4 adverse reaction</td><td class='t-content' style='border-bottom-right-radius:5px;'>Permanently discontinue</td></tr><tr><td class='t-content' style='border-bottom-left-radius:5px;'>Grade 3 myocarditis</td><td class='t-content' style='border-bottom-right-radius:5px;'>Permanently discontinue</td></tr><tr><td class='t-content' style='border-bottom-left-radius:5px;'>Requirement for ≥10 mg per day prednisone or equivalent for &#62;12 weeks</td><td class='t-content' style='border-bottom-right-radius:5px;'>Permanently discontinue</td></tr><tr><td class='t-content' style='border-bottom-left-radius:5px;'>Persistent Grade 2 or 3 adverse reactions lasting <nobr>12 weeks</nobr> or longer</td><td class='t-content' style='border-bottom-right-radius:5px;'>Permanently discontinue</td></tr></table><p style='font-size:12px!important;margin-bottom:5px;margin-top:15px;'><span style='display: inline-block;text-indent: -5px;'>*</span>Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events. <nobr>(NCI CTCAE) v4.0.</nobr></p><p style='font-size:12px!important;margin-bottom:10px;'><span style='display: inline-block;text-indent: -5px;'><sup>&dagger;</sup></span>Resume treatment when adverse reaction improves to Grade <nobr>0 or 1.</nobr></p><p style='font-size:12px!important;'>ALT=alanine aminotransferase; AST=aspartate aminotransferase; SJS=Stevens-Johnson syndrome; TEN=toxic epidermal necrolysis; ULN=upper limit of normal.</p>",
                                    "What other adverse reactions do you want to see the recommended dose modifications for <nobr>OPDIVO<sup>&reg;</sup>?</nobr>"
                                ],
                                "suggest": [
                                    303,
                                    304,
                                    305,
                                    300
                                ]
                            },
                             {
                                "id": 4,
                                "title": "Safety",
                                "objective": "4",
                                "prompt": [
                                    "What is the selected safety profile for OPDIVO for patients with previously treated mNSCLC? "
                                ],
                                "answer": [
                                    "What safety and tolerability topic would you like to explore?"
                                ],
                                "suggest": [
                                    401
                                ]
                            },
                            {
                                "id": 100,
                                "title": "Something Else",
                                "objective": "1",
                                "prompt": [
                                    "I'd like to see another topic."
                                ],
                                "answer": [
                                    "Would you like to learn more about OPDIVO for patients with NSCLC with progression on or after <nobr>platinum-based</nobr> chemotherapy?"
                                ],
                                "suggest": [
                                    1,
                                    2,
                                    4,
                                    3,
                                    600,
                                    700
                                ]
                            },
                            {
                                "id": 400,
                                "title": "Something Else",
                                "objective": "4",
                                "prompt": [
                                    "I'd like to see another topic."
                                ],
                                "answer": [
                                    "Would you like to learn more about OPDIVO in patients with previously treated mNSCLC?"
                                ],
                                "suggest": [
                                    1,
                                    2,
                                    4,
                                    3,
                                    600,
                                    700
                                ]
                            },
                            {
                                "id": 401,
                                "title": "Adverse Reactions",
                                "objective": "4",
                                "prompt": [
                                    "What were the adverse reactions from <nobr>Checkmate 017</nobr> <nobr>and 057?</nobr>"
                                ],
                                "answer": [
                                    "<p style='font-size: 12px !important;text-align: right;margin-bottom: 15px;'>Scroll down for more content</p>Sure. Here were adverse reactions reported in Checkmate 017 and 057 <reference id='1'>[OPDIVO PI]</reference><ul><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>The safety profile of OPDIVO<sup>&reg;</sup> was evaluated across squamous and <nobr>non-squamous</nobr> histologies in patients with previously treated mNSCLC</span></li><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>The most common adverse reactions (reported in ≥20% of patients) were fatigue, musculoskeletal pain, cough, dyspnea, and decreased <nobr>appetite <reference id='1'>[OPDIVO PI]</reference></nobr></span></li><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>Serious adverse reactions occurred in 46% of patients receiving <nobr>OPDIVO <reference id='1'>[OPDIVO PI]</reference></nobr></span></li></ul><div style='transform:translate(12px);padding-left: 20px;'><div style='transform:translate(-12px, -3px);position:absolute;color:#f26322;'>&ndash;</div><p style='margin-bottom: 10px;'>The most frequent serious adverse reactions reported in &ge;2% of patients receiving OPDIVO were pneumonia, pulmonary embolism, dyspnea, pyrexia, pleural effusion, pneumonitis, and respiratory failure</p></div><div style='transform:translate(12px);padding-left: 20px;'><div style='transform:translate(-12px, -3px);position:absolute;color:#f26322;'>&ndash;</div><p style='margin-bottom: 10px;'>OPDIVO was discontinued due to adverse reactions in 11% of <nobr>patients <reference id='1'>[OPDIVO PI]</reference></nobr></p></div><div style='transform:translate(12px);padding-left: 20px;'><div style='transform:translate(-12px, -3px);position:absolute;color:#f26322;'>&ndash;</div><p style='margin-bottom: 10px;'>28% of patients receiving OPDIVO had a drug delay for an adverse <nobr>reaction <reference id='1'>[OPDIVO PI]</reference></nobr></p></div><p style='font-size:16px!important;margin-top:15px;'><strong>Adverse Reactions Occurring in ≥10% (All Grades) of OPDIVO-Treated Patients and at a Higher Incidence than Docetaxel (Between Arm Difference of ≥5% [All Grades] or ≥2% <nobr>[Grades 3-4])</nobr> in <nobr>Checkmate 017</nobr> and <nobr>Checkmate 057</nobr></strong></p><p style='margin-bottom:15px;font-weight:bold;margin-top:15px;'>ALL GRADES</p><table class='table-105' style='border-collapse: inherit;'><tr><th style='border-bottom:1px solid #dadada;background-color:white;'></th><th style='background-color:#009ABD;border-bottom:1px solid #dadada;'>OPDIVO <br>(n=418)</th><th style='background-color:#999999;border-bottom:1px solid #dadada;border-top-right-radius:5px;'>DOCETAXEL <br>(n=397)</th></tr><tr><td style='border-bottom:1px solid #dadada;'></td><td style='border-bottom:1px solid #dadada;'><strong>All Grades (%)</strong></td><td style='border-bottom:1px solid #dadada;'><strong>All Grades (%)</strong></td></tr><tr><td><strong>Respiratory, Thoracic, and Mediastinal Disorders</strong></td><td></td><td></td></tr><tr><td style='border-bottom:1px solid #dadada;'>Cough</td><td style='border-bottom:1px solid #dadada;'><strong>31</strong></td><td style='border-bottom:1px solid #dadada;'><strong>24</strong></td></tr><tr><td><strong>Metabolism and Nutrition Disorders</strong></td><td></td><td></td></tr><tr><td style='border-bottom:1px solid #dadada;'>Decreased appetite</td><td style='border-bottom:1px solid #dadada;'><strong>28</strong></td><td style='border-bottom:1px solid #dadada;'><strong>23</strong></td></tr><tr><td><strong>Skin and Subcutaneous Tissue Disorders</strong></td><td></td><td></td></tr><tr><td style='border-bottom:1px solid #dadada;border-bottom-left-radius:7px;'>Pruritus</td><td style='border-bottom:1px solid #dadada;'><strong>10</strong></td><td style='border-bottom:1px solid #dadada;border-bottom-right-radius:5px;'><strong>2.0</strong></td></tr></table><p style='margin-top:15px;margin-bottom:15px;font-weight:bold;'>GRADES 3-4</p><table class='table-105' style='border-collapse: inherit;'><tr><th style='border-bottom:1px solid #dadada;background-color:white;'></th><th style='background-color:#009ABD;border-bottom:1px solid #dadada;'>OPDIVO <br>(n=418)</th><th style='background-color:#999999;border-bottom:1px solid #dadada;border-top-right-radius:5px;'>DOCETAXEL <br>(n=397)</th></tr><tr><td style='border-bottom:1px solid #dadada;'></td><td style='border-bottom:1px solid #dadada;'><strong>Grades 3-4 (%)</strong></td><td style='border-bottom:1px solid #dadada;'><strong>Grades 3-4 (%)</strong></td></tr><tr><td><strong>Respiratory, Thoracic, and Mediastinal Disorders</strong></td><td></td><td></td></tr><tr><td style='border-bottom:1px solid #dadada;'>Cough</td><td style='border-bottom:1px solid #dadada;'><strong>0.7</strong></td><td style='border-bottom:1px solid #dadada;'><strong>0</strong></td></tr><tr><td><strong>Metabolism and Nutrition Disorders</strong></td><td></td><td></td></tr><tr><td style='border-bottom:1px solid #dadada;'>Decreased appetite</td><td style='border-bottom:1px solid #dadada;'><strong>1.4</strong></td><td style='border-bottom:1px solid #dadada;'><strong>1.5</strong></td></tr><tr><td><strong>Skin and Subcutaneous Tissue Disorders</strong></td><td></td><td></td></tr><tr><td style='border-bottom:1px solid #dadada;border-bottom-left-radius:7px;'>Pruritus</td><td style='border-bottom:1px solid #dadada;'><strong>0.2</strong></td><td style='border-bottom:1px solid #dadada;border-bottom-right-radius:5px;'><strong>0</strong></td></tr></table><p style='margin-top:15px;'>Toxicity was graded per NCI CTCAE&nbsp;v4.</p>",
                                    "What other safety profile topic would you like to explore?"
                                ],
                                "suggest": [
                                    402,
                                    403,
                                    400
                                ]
                            },
                            {
                                "id": 402,
                                "title": "Laboratory Abnormalities",
                                "objective": "4",
                                "prompt": [
                                    "Show me the laboratory abnormalities in CHECKMATE 057 and 017."
                                ],
                                "answer": [
                                    "I can tell you that. For previously treated metastatic NSCLC, laboratory abnormalities in <nobr>Checkmate 057</nobr> and 017 were as follows <reference id='1'>[OPDIVO PI]</reference>.",
                                    "Note that these are laboratory abnormalities worsening from baseline occurring in ≥10% of OPDIVO-treated patients for all NCI CTCAE grades and at a higher incidence than docetaxel (between arm difference of ≥5% [All Grades] or ≥2% <nobr>[Grades 3-4])</nobr> in <nobr>Checkmate 017</nobr> and <nobr>Checkmate 057.</nobr>",
                                    "<p style='font-size: 12px !important;text-align: right;margin-bottom: 15px;'>Scroll down for more content</p><p style='font-size:16px!important;margin-top:15px;'><strong>ALL GRADES<br>Percentage of Patients With Worsening Lab Test From Baseline*</strong></p><table class='table-105' style='border-collapse: inherit;'><tr><th style='border-bottom:1px solid #dadada;background-color:white;'></th><th style='background-color:#009ABD;border-bottom:1px solid #dadada;'>OPDIVO</th><th style='background-color:#999999;border-bottom:1px solid #dadada;border-top-right-radius:5px;'>DOCETAXEL</th></tr><tr><td style='border-bottom:1px solid #dadada;'></td><td style='border-bottom:1px solid #dadada;'><strong>All Grades (%)</strong></td><td style='border-bottom:1px solid #dadada;'><strong>All Grades (%)</strong></td></tr><tr><td><strong>Chemistry</strong></td><td></td><td></td></tr><tr><td>Hyponatremia</td><td><strong>35</strong></td><td><strong>34</strong></td></tr><tr><td>Increased AST</td><td><strong>27</strong></td><td><strong>13</strong></td></tr><tr><td>Increased alkaline phosphatase</td><td><strong>26</strong></td><td><strong>18</strong></td></tr><tr><td>Increased ALT</td><td><strong>22</strong></td><td><strong>17</strong></td></tr><tr><td>Increased creatinine</td><td><strong>18</strong></td><td><strong>12</strong></td></tr><tr><td style='border-bottom:1px solid #dadada;border-bottom-left-radius:7px;'>Increased TSH<sup>&dagger;</sup></td><td style='border-bottom:1px solid #dadada;'><strong>14</strong></td><td style='border-bottom:1px solid #dadada;border-bottom-right-radius:5px;'><strong>6</strong></td></tr></table><p style='font-size:16px!important;margin-top:15px;margin-bottom:15px;'><strong>GRADES 3-4 <br>Percentage of Patients With Worsening Lab Test From Baseline*</strong></p><table class='table-105' style='border-collapse: inherit;'><tr><th style='border-bottom:1px solid #dadada;background-color:white;'></th><th style='background-color:#009ABD;border-bottom:1px solid #dadada;'>OPDIVO</th><th style='background-color:#999999;border-bottom:1px solid #dadada;border-top-right-radius:5px;'>DOCETAXEL</th></tr><tr><td style='border-bottom:1px solid #dadada;'></td><td style='border-bottom:1px solid #dadada;'><strong>Grades 3-4 (%)</strong></td><td style='border-bottom:1px solid #dadada;'><strong>Grades 3-4 (%)</strong></td></tr><tr><td><strong>Chemistry</strong></td><td></td><td></td></tr><tr><td>Hyponatremia</td><td><strong>7</strong></td><td><strong>4.9</strong></td></tr><tr><td>Increased AST</td><td><strong>1.9</strong></td><td><strong>0.8</strong></td></tr><tr><td>Increased alkaline phosphatase</td><td><strong>0.7</strong></td><td><strong>0.8</strong></td></tr><tr><td>Increased ALT</td><td><strong>1.7</strong></td><td><strong>0.5</strong></td></tr><tr><td>Increased creatinine</td><td><strong>0</strong></td><td><strong>0.5</strong></td></tr><tr><td style='border-bottom:1px solid #dadada;border-bottom-left-radius:7px;'>Increased TSH<sup>&dagger;</sup></td><td style='border-bottom:1px solid #dadada;'><strong>N/A</strong></td><td style='border-bottom:1px solid #dadada;border-bottom-right-radius:5px;'><strong>N/A</strong></td></tr></table><p style='margin-top:15px;margin-bottom:0;font-size:12px!important;'>TSH: OPDIVO group (n=314) and docetaxel group <nobr>(n=297).</nobr></p><p style='font-size:12px!important;margin-bottom:5px;margin-top:15px;'><span style='display: inline-block;text-indent: -5px;'>*</span>Each test incidence is based on the number of patients who had both baseline and at least one <nobr>on-study</nobr> laboratory measurement available: OPDIVO group (range: 405 to <nobr>417 patients)</nobr> and docetaxel group (range: 372 to <nobr>390 patients).</nobr></p><p style='font-size:12px!important;margin-bottom:5px;margin-top:15px;'><span style='display: inline-block;text-indent: -5px;'><sup>&dagger;</sup></span>Not graded per National Cancer Institute Common Terminology Criteria for Adverse <nobr>Events v4.0.</nobr></p><p style='font-size:12px!important;'>ALT=alanine aminotransferase; AST=aspartate aminotransferase; NCI CTCAE=National Cancer Institute Common Terminology Criteria for Adverse Events; TSH=thyroid-stimulating hormone.</p>",
                                    "What other safety profile topic would you like to explore?"
                                ],
                                "suggest": [
                                    401,
                                    403,
                                    400
                                ]
                            },
                            {
                                "id": 403,
                                "title": "Immune-Mediated Adverse Reactions Data",
                                "objective": "4",
                                "prompt": [
                                    "Show me the incidence and onset of immune-mediated adverse reactions."
                                ],
                                "answer": [
                                    "Sure. Here is the incidence and onset of <nobr>immune-mediated</nobr> adverse reactions <reference id='1'>[OPDIVO PI]</reference> with OPDIVO<sup>&reg;</sup> as a single agent <nobr>(n=1994).</nobr>",
                                    "<p style='font-size: 12px !important;text-align: right;margin-bottom: 15px;'>Scroll down for more content</p><table class='table-403' style='border-collapse: inherit;'><tr><th style='border-bottom:1px solid #dadada;background-color:white;'></th><th style='background-color:#009ABD;border-bottom:1px solid #dadada;'>Incidence All Grades n (%)</th><th style='background-color:#009ABD;border-bottom:1px solid #dadada;border-top-right-radius:5px;'>Median Time to Onset, Months (range)</th></tr><tr><td style='border-bottom:1px solid #dadada;'></td><td style='border-bottom:1px solid #dadada;'><strong>Grades 3-4 (%)</strong></td><td style='border-bottom:1px solid #dadada;'><strong>Grades 3-4 (%)</strong></td></tr><tr><td><strong>Pneumonitis*</strong></td><td>61 (3.1)</td><td>3.5 (1 day to 22.3 months)</td></tr><tr><td><strong>Colitis</strong></td><td>58 (2.9)</td><td>5.3 (2 days to 20.9 months)</td></tr><tr><td><strong>Hepatitis</strong></td><td>35 (1.8)</td><td>3.3 (6 days to 9 months)</td></tr><tr><td style='border-bottom:none;'><strong>Endocrinopathies</strong></td><td style='border-bottom:none;'></td><td style='border-bottom:none;'></td></tr><tr><td>Hypophysitis</td><td>12 (0.6)</td><td>4.9 (1.4 to 11 months)</td></tr><tr><td>Adrenal Insufficiency</td><td>20 (1)</td><td>4.3 (15 days to 21 months)</td></tr><tr><td class='break-m'><span>Hypothyroidism/Thyroiditis</span></td><td>171 (9)</td><td>2.9 (1 day to 16.6 months)</td></tr><tr><td>Hyperthyroidism</td><td>54 (2.7)</td><td>1.5 (1 day to 14.2 months)</td></tr><tr><td>Diabetes</td><td>17<sup>&dagger;</sup> (0.9)</td><td>4.4 (15 days to 22 months)</td></tr><tr><td><strong>Nephritis/Renal Dysfunction</strong></td><td>23 (1.2)</td><td>4.6 (23 days to 12.3 months)</td></tr><tr><td><strong>Skin<sup>&Dagger;</sup></strong></td><td>171 (9)</td><td>2.8 (&#60;1 day to 25.8 months)</td></tr><td style='border-bottom:1px solid #dadada;border-bottom-left-radius:7px;'><strong>Encephalitis</strong></td><td style='border-bottom:1px solid #dadada;'>3<sup>&sect;</sup> (0.2)</td><td style='border-bottom:1px solid #dadada;border-bottom-right-radius:5px;'>--</td></tr></table><p style='font-size:12px!important;margin-bottom:12px;margin-top:15px;'><span style='display: inline-block;text-indent: -5px;'>*</span>Fatal cases have been reported.</p><p style='font-size:12px!important;margin-bottom:12px;'><span style='display: inline-block;text-indent: -5px;'><sup>&dagger;</sup></span>Two cases of diabetic ketoacidosis occurred.</p><p style='font-size:12px!important;margin-bottom:12px;'><span style='display: inline-block;text-indent: -5px;'><sup>&Dagger;</sup></span>OPDIVO can cause skin <nobr>immune-mediated</nobr> adverse reactions including <nobr>Stevens-Johnson</nobr> syndrome (SJS) and toxic epidermal necrolysis (TEN); some cases with fatal outcome.</p><p style='font-size:12px!important;margin-bottom:12px;'><span style='display: inline-block;text-indent: -5px;'><sup>&sect;</sup></span>Fatal limbic encephalitis occurred in 1 patient after <nobr>7.2 months</nobr> of exposure despite discontinuation of OPDIVO and administration of corticosteroids. In the other 2 patients, encephalitis occurred post-allogeneic hematopoietic stem cell transplantation.</p>",
                                    "And, here are some infusion-related reactions:<ul style='margin-top:0;'><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>Infusion-related reactions occured in 6.4% (127/1994) of patients</span></li><li style='color:#f26322;margin-bottom: 10px;'><span style='color:#666;'>Median time to onset not available</span></li></ul>"
                                ],
                                "suggest": [
                                    404,
                                    400
                                ]
                            },
                            {
                                "id": 404,
                                "title": "Additional Information on Adverse Reactions",
                                "objective": "4",
                                "prompt": [
                                    "Show me additional information for the <nobr>immune-mediated</nobr> adverse reactions."
                                ],
                                "answer": [
                                    "Additional information on immune-mediated adverse reactions with OPDIVO<sup>&reg;</sup> as a single agent is in the table below.",
                                    "<p style='font-size: 12px !important;text-align: right;margin-bottom: 15px;'>Scroll down for more content</p><table class='table-403 table-405' style='border-collapse: inherit;'><tr><th colspan='2' style='background-color:#009ABD;border-bottom:1px solid #dadada;padding:10px 0;'>Pneumonitis (n=61)</th></tr><tr><td style='border-bottom:1px solid #dadada;'><strong>Permanently Discontinued OPDIVO (%)</strong></td><td style='border-bottom:1px solid #dadada;'>1.1</td></tr><tr><td><strong>Withheld OPDIVO (%)</strong></td><td>1.3</td></tr><tr><td style='border-bottom:none;'><strong>Corticosteroid Use</strong></td><td style='border-bottom:none;'></td></tr><tr><td>(%)</td><td>~89<sup>&Dagger;</sup></td></tr><tr><td>Median Duration, Days (Range)</td><td>26 (1 day to 6 mos)</td></tr><tr><td><strong>Other Treatments</strong></td><td>--</td></tr><tr><td><strong>Resolution<sup>&dagger;</sup> (%)</strong></td><td>67<sup>&sect;</sup></td></tr><tr><td><strong>Recurrence After Re-Initiation of OPDIVO (%)</strong></td><td>~8</td></tr><tr><th colspan='2' style='background-color:#009ABD;border-bottom:1px solid #dadada;padding:10px 0;border-top-left-radius: 0px;'>Colitis (n=58)</th></tr><tr><td><strong>Permanently Discontinued OPDIVO (%)</strong></td><td>0.7</td></tr><tr><td><strong>Withheld OPDIVO (%)</strong></td><td>1</td></tr><tr><td style='border-bottom:none;'><strong>Corticosteroid Use</strong></td><td style='border-bottom:none;'></td></tr><tr><td>(%)</td><td>~91<sup>&Dagger;</sup></td></tr><tr><td>Median Duration, Days (Range)</td><td>23<br>(1 day to 9.3 mos)</td></tr><tr><td><strong>Other Treatments</strong></td><td>4 patients received infliximab in addition to <nobr>high-dose CS</nobr></td></tr><tr><td><strong>Resolution<sup>&dagger;</sup> (%)</strong></td><td>74<sup>||</sup></td></tr><tr><td><strong>Recurrence After <nobr>Re-Initiation</nobr> of OPDIVO (%)</strong></td><td>~16</td></tr><tr><th colspan='2' style='background-color:#009ABD;border-bottom:1px solid #dadada;padding:10px 0;border-top-left-radius: 0px;'>Hepatitis (n=35)</th></tr><tr><td><strong>Permanently Discontinued OPDIVO (%)</strong></td><td>0.7</td></tr><tr><td><strong>Withheld OPDIVO (%)</strong></td><td>1</td></tr><tr><td style='border-bottom:none;'><strong>Corticosteroid Use</strong></td><td style='border-bottom:none;'></td></tr><tr><td>(%)</td><td>~100<sup>&Dagger;</sup></td></tr><tr><td>Median Duration, Days (Range)</td><td>23<br>(1 day to 2 mos)</td></tr><tr><td><strong>Other Treatments</strong></td><td>2 patients received mycophenolic acid in addition to <nobr>high-dose CS</nobr></td></tr><tr><td><strong>Resolution<sup>&dagger;</sup> (%)</strong></td><td>74<sup>||</sup></td></tr><tr><td><strong>Recurrence After <nobr>Re-Initiation</nobr> of OPDIVO (%)</strong></td><td>~29</td></tr><tr><td colspan='2' style='background-color:#009ABD;border-bottom:1px solid #dadada;padding:10px 0;  color: white;text-align: center;'><strong>Endocrinopathies</strong><br>Hypophysitis (n=12)</td></tr><tr><td style='border-bottom:1px solid #dadada;'><strong>Permanently Discontinued OPDIVO (%)</strong></td><td style='border-bottom:1px solid #dadada;'>0.1</td></tr><tr><td><strong>Withheld OPDIVO (%)</strong></td><td>0.2</td></tr><tr><td style='border-bottom:none;'><strong>Corticosteroid Use</strong></td><td style='border-bottom:none;'></td></tr><tr><td>(%)</td><td>33<sup>&Dagger;</sup></td></tr><tr><td>Median Duration, Days (Range)</td><td>14<br>(5 to 26 days)</td></tr><tr><td><strong>Other Treatments</strong></td><td>~67% received HRT</td></tr><tr><td><strong>Resolution<sup>&dagger;</sup> (%)</strong></td><td>--</td></tr><tr><td><strong>Recurrence After Re-Initiation of OPDIVO (%)</strong></td><td>--</td></tr><tr><th colspan='2' style='background-color:#009ABD;border-bottom:1px solid #dadada;padding:10px 0;border-top-left-radius: 0px;'><strong>Endocrinopathies</strong><br>Adrenal Insufficiency (n=20)</th></tr><tr><td><strong>Permanently Discontinued OPDIVO (%)</strong></td><td>0.1</td></tr><tr><td><strong>Withheld OPDIVO (%)</strong></td><td>0.5</td></tr><tr><td style='border-bottom:none;'><strong>Corticosteroid Use</strong></td><td style='border-bottom:none;'></td></tr><tr><td>(%)</td><td>25<sup>&Dagger;</sup></td></tr><tr><td>Median Duration, Days (Range)</td><td>11<br>(1 day to 1 mo)</td></tr><tr><td><strong>Other Treatments</strong></td><td>~85% received HRT</td></tr><tr><td><strong>Resolution<sup>&dagger;</sup> (%)</strong></td><td>--</td></tr><tr><td><strong>Recurrence After <nobr>Re-Initiation</nobr> of OPDIVO (%)</strong></td><td>--</td></tr><tr><th colspan='2' style='background-color:#009ABD;border-bottom:1px solid #dadada;padding:10px 0;border-top-left-radius: 0px;'><strong>Endocrinopathies</strong><br>Hypothyroidism/Thyroiditis (n=171)</th></tr><tr><td><strong>Permanently Discontinued OPDIVO (%)</strong></td><td>--</td></tr><tr><td><strong>Withheld OPDIVO (%)</strong></td><td>--</td></tr><tr><td style='border-bottom:none;'><strong>Corticosteroid Use</strong></td><td style='border-bottom:none;'></td></tr><tr><td>(%)</td><td>4</td></tr><tr><td>Median Duration, Days (Range)</td><td>--</td></tr><tr><td><strong>Other Treatments</strong></td><td>~79% received levothyroxine and 4% also required corticosteroids</td></tr><tr><td><strong>Resolution<sup>&dagger;</sup> (%)</strong></td><td>35</td></tr><tr><td><strong>Recurrence After <nobr>Re-Initiation</nobr> of OPDIVO (%)</strong></td><td>--</td></tr><tr><th colspan='2' style='background-color:#009ABD;border-bottom:1px solid #dadada;padding:10px 0;border-top-left-radius: 0px;'><strong>Endocrinopathies</strong><br>Hyperthyroidism (n=54)</th></tr><tr><td><strong>Permanently Discontinued OPDIVO (%)</strong></td><td>--</td></tr><tr><td><strong>Withheld OPDIVO (%)</strong></td><td>--</td></tr><tr><td style='border-bottom:none;'><strong>Corticosteroid Use</strong></td><td style='border-bottom:none;'></td></tr><tr><td>(%)</td><td>9</td></tr><tr><td>Median Duration, Days (Range)</td><td>--</td></tr><tr><td><strong>Other Treatments</strong></td><td>~26% received methimazole; ~9% received carbimazole; ~4% received propylthiouracil</td></tr><tr><td><strong>Resolution<sup>&dagger;</sup> (%)</strong></td><td>76</td></tr><tr><td><strong>Recurrence After <nobr>Re-Initiation</nobr> of OPDIVO (%)</strong></td><td>--</td></tr><tr><th colspan='2' style='background-color:#009ABD;border-bottom:1px solid #dadada;padding:10px 0;border-top-left-radius: 0px;'><strong>Endocrinopathies</strong><br>Diabetes (n=17)</th></tr><tr><td><strong>Permanently Discontinued OPDIVO (%)</strong></td><td>--</td></tr><tr><td><strong>Withheld OPDIVO (%)</strong></td><td>--</td></tr><tr><td style='border-bottom:none;'><strong>Corticosteroid Use</strong></td><td style='border-bottom:none;'></td></tr><tr><td>(%)</td><td>--</td></tr><tr><td>Median Duration, Days (Range)</td><td>--</td></tr><tr><td><strong>Other Treatments</strong></td><td>--</td></tr><tr><td><strong>Resolution<sup>&dagger;</sup> (%)</strong></td><td>--</td></tr><tr><td><strong>Recurrence After <nobr>Re-Initiation</nobr> of OPDIVO (%)</strong></td><td>--</td></tr><tr><th colspan='2' style='background-color:#009ABD;border-bottom:1px solid #dadada;padding:10px 0;border-top-left-radius: 0px;'><strong>Nephritis/Renal Dysfunction</strong> (n=23)</th></tr><tr><td><strong>Permanently Discontinued OPDIVO (%)</strong></td><td>0.3</td></tr><tr><td><strong>Withheld OPDIVO (%)</strong></td><td>0.8</td></tr><tr><td style='border-bottom:none;'><strong>Corticosteroid Use</strong></td><td style='border-bottom:none;'></td></tr><tr><td>(%)</td><td>100<sup>&Dagger;</sup></td></tr><tr><td>Median Duration, Days (Range)</td><td>21 (1 day to 15.4 mos)</td></tr><tr><td><strong>Other Treatments</strong></td><td>--</td></tr><tr><td><strong>Resolution<sup>&dagger;</sup> (%)</strong></td><td>48<sup>||</sup></td></tr><tr><td><strong>Recurrence After <nobr>Re-Initiation</nobr> of OPDIVO (%)</strong></td><td>0</td></tr><tr><th colspan='2' style='background-color:#009ABD;border-bottom:1px solid #dadada;padding:10px 0;border-top-left-radius: 0px;'><strong>Skin<sup>||</sup></strong> (n=171)</th></tr><tr><td><strong>Permanently Discontinued OPDIVO (%)</strong></td><td>0.3</td></tr><tr><td><strong>Withheld OPDIVO (%)</strong></td><td>0.8</td></tr><tr><td style='border-bottom:none;'><strong>Corticosteroid Use</strong></td><td style='border-bottom:none;'></td></tr><tr><td>(%)</td><td>~16<sup>&Dagger;</sup></td></tr><tr><td>Median Duration, Days (Range)</td><td>12 (1 day to 8.9 mos)</td></tr><tr><td><strong>Other Treatments</strong></td><td>85% received topical CS</td></tr><tr><td><strong>Resolution<sup>&dagger;</sup> (%)</strong></td><td>48<sup>||</sup></td></tr><tr><td><strong>Recurrence After <nobr>Re-Initiation</nobr> of OPDIVO (%)</strong></td><td>1.4</td></tr><tr><th colspan='2' style='background-color:#009ABD;border-bottom:1px solid #dadada;padding:10px 0;border-top-left-radius: 0px;'><strong>Encephalitis</strong> (n=3)</th></tr><tr><td><strong>Permanently Discontinued OPDIVO (%)</strong></td><td>--</td></tr><tr><td><strong>Withheld OPDIVO (%)</strong></td><td>--</td></tr><tr><td style='border-bottom:none;'><strong>Corticosteroid Use</strong></td><td style='border-bottom:none;'></td></tr><tr><td>(%)</td><td>--</td></tr><tr><td>Median Duration, Days (Range)</td><td>--</td></tr><tr><td><strong>Other Treatments</strong></td><td>--</td></tr><tr><td><strong>Resolution<sup>&dagger;</sup> (%)</strong></td><td>--</td></tr><tr><td style='border-bottom-left-radius:5px;'><strong>Recurrence After <nobr>Re-Initiation</nobr> of OPDIVO (%)</strong></td><td style='border-bottom-right-radius:5px;'>--</td></tr></table><p style='font-size:12px!important;margin-bottom:5px;margin-top:15px;'><span style='display: inline-block;text-indent: -5px;'>*</span>The chart reflects exposure to OPDIVO as a single agent, for clinically significant adverse reactions in 1994 patients across select approved indications. Please see OPDIVO <a href='http://packageinserts.bms.com/pi/pi_opdivo.pdf' target='_blank' style='font-weight:bold;color:#003B5C;'>US Full Prescribing Information</a> for full safety information.</p><p style='font-size:12px!important;'><span style='display: inline-block;text-indent: -5px;'><sup>&dagger;</sup></span>In the context of the IMAE time-to-resolution analyses, resolution date was defined as the <nobr>investigator-assessed</nobr> IMAE resolution date. In the analyses of complete resolution, complete resolution was defined as improved to Grade 0 or baseline grade per investigator assessment with completion of corticosteroid treatment (or other medical intervention).</p><p style='font-size:12px!important;'><span style='display: inline-block;text-indent: -5px;'><sup>&Dagger;</sup></span>At least 40 mg prednisone equivalent per day.</p><p style='font-size:12px!important;'><span style='display: inline-block;text-indent: -5px;'><sup>&sect;</sup></span>Complete resolution following CS taper.</p><p style='font-size:12px!important;'><span style='display: inline-block;text-indent: -5px;'><sup>||</sup></span>Complete resolution following CS use.</p><p style='font-size:12px!important;'>CS=corticosteroids; HRT=hormone-replacement therapy; mo/mos=month/months; IMAE=immune-mediated adverse event.</p>"
                                ],
                                "suggest": [
                                    400
                                ]
                            },
                            {
                                "id": 405,
                                "title": "Pneumonitis, Colitis &amp; Hepatitis",
                                "objective": "4",
                                "prompt": [
                                    ""
                                ],
                                "answer": [
                                    ""
                                ],
                                "suggest": [
                                    406,
                                    407,
                                    408
                                ]
                            },
                            {
                                "id": 406,
                                "title": "Endocrinopathies",
                                "objective": "4",
                                "prompt": [
                                    "Show me additional information for the <nobr>immune-mediated</nobr> adverse reactions for endocrinopathies."
                                ],
                                "answer": [
                                    ""
                                ],
                                "suggest": [
                                    405,
                                    407,
                                    408
                                ]
                            },
                            {
                                "id": 407,
                                "title": "Nephritis and Renal Dysfunction",
                                "objective": "4",
                                "prompt": [
                                    "Show me additional information for the immune-mediated adverse reactions for nephritis and renal dysfunction."
                                ],
                                "answer": [
                                    "Additional information on immune-mediated adverse reactions with OPDIVO<sup>&reg;</sup> as a single agent for pneumonitis, colitis and hepatitis is in the table below.",
                                    "<p style='font-size: 12px !important;text-align: right;margin-bottom: 15px;'>Scroll down for more content</p><table class='table-403 table-405' style='border-collapse: inherit;'><tr><th colspan='2' style='background-color:#009ABD;border-bottom:1px solid #dadada;padding:10px 0;border-top-left-radius: 0px;'><strong>Nephritis/Renal Dysfunction</strong> (n=23)</th></tr><tr><td><strong>Permanently Discontinued OPDIVO (%)</strong></td><td>0.3</td></tr><tr><td><strong>Withheld OPDIVO (%)</strong></td><td>0.8</td></tr><tr><td style='border-bottom:none;'><strong>Corticosteroid Use</strong></td><td style='border-bottom:none;'></td></tr><tr><td>(%)</td><td>100<sup>&Dagger;</sup></td></tr><tr><td>Median Duration, Days (Range)</td><td>21 (1 day to 15.4 mos)</td></tr><tr><td><strong>Other Treatments</strong></td><td>--</td></tr><tr><td><strong>Resolution<sup>&dagger;</sup> (%)</strong></td><td>48<sup>||</sup></td></tr><tr><td style='border-bottom-left-radius:5px;'><strong>Recurrence After <nobr>Re-Initiation</nobr> of OPDIVO (%)</strong></td><td style='border-bottom-right-radius:5px;'>0</td></tr></table><p style='font-size:12px!important;margin-bottom:5px;margin-top:15px;'><span style='display: inline-block;text-indent: -5px;'>*</span>The chart reflects exposure to OPDIVO as a single agent, for clinically significant adverse reactions in 1994 patients across select approved indications. Please see OPDIVO <a href='http://packageinserts.bms.com/pi/pi_opdivo.pdf' target='_blank' style='font-weight:bold;color:#003B5C;'>US Full Prescribing Information</a> for full safety information.</p><p style='font-size:12px!important;'><span style='display: inline-block;text-indent: -5px;'><sup>&dagger;</sup></span>In the context of the IMAE time-to-resolution analyses, resolution date was defined as the <nobr>investigator-assessed</nobr> IMAE resolution date. In the analyses of complete resolution, complete resolution was defined as improved to Grade 0 or baseline grade per investigator assessment with completion of corticosteroid treatment (or other medical intervention).</p><p style='font-size:12px!important;'><span style='display: inline-block;text-indent: -5px;'><sup>&Dagger;</sup></span>At least 40 mg prednisone equivalent per day.</p><p style='font-size:12px!important;'><span style='display: inline-block;text-indent: -5px;'><sup>&sect;</sup></span>Complete resolution following CS taper.</p><p style='font-size:12px!important;'><span style='display: inline-block;text-indent: -5px;'><sup>||</sup></span>Complete resolution following CS use.</p><p style='font-size:12px!important;'>CS=corticosteroids; HRT=hormone-replacement therapy; mo/mos=month/months; IMAE=immune-mediated adverse event.</p>",
                                    "Which immune-mediated adverse reactions would you like additional <nobr>information on?</nobr>"
                                ],
                                "suggest": [
                                    405,
                                    406,
                                    408
                                ]
                            },
                            {
                                "id": 408,
                                "title": "Skin &amp; Encephalitis",
                                "objective": "4",
                                "prompt": [
                                    "Show me additional information for the immune-mediated adverse reactions for skin reactions and encephalitis."
                                ],
                                "answer": [
                                    "Additional information on immune-mediated adverse reactions with OPDIVO<sup>&reg;</sup> as a single agent for pneumonitis, colitis and hepatitis is in the table below.",
                                    "<p style='font-size: 12px !important;text-align: right;margin-bottom: 15px;'>Scroll down for more content</p><table class='table-403 table-405' style='border-collapse: inherit;'><tr><th colspan='2' style='background-color:#009ABD;border-bottom:1px solid #dadada;padding:10px 0;border-top-left-radius: 0px;'><strong>Skin<sup>||</sup></strong> (n=171)</th></tr><tr><td><strong>Permanently Discontinued OPDIVO (%)</strong></td><td>0.3</td></tr><tr><td><strong>Withheld OPDIVO (%)</strong></td><td>0.8</td></tr><tr><td style='border-bottom:none;'><strong>Corticosteroid Use</strong></td><td style='border-bottom:none;'></td></tr><tr><td>(%)</td><td>~16<sup>&Dagger;</sup></td></tr><tr><td>Median Duration, Days (Range)</td><td>12 (1 day to 8.9 mos)</td></tr><tr><td><strong>Other Treatments</strong></td><td>85% received topical CS</td></tr><tr><td><strong>Resolution<sup>&dagger;</sup> (%)</strong></td><td>48<sup>||</sup></td></tr><tr><td><strong>Recurrence After <nobr>Re-Initiation</nobr> of OPDIVO (%)</strong></td><td>1.4</td></tr><tr><th colspan='2' style='background-color:#009ABD;border-bottom:1px solid #dadada;padding:10px 0;border-top-left-radius: 0px;'><strong>Encephalitis</strong> (n=3)</th></tr><tr><td><strong>Permanently Discontinued OPDIVO (%)</strong></td><td>--</td></tr><tr><td><strong>Withheld OPDIVO (%)</strong></td><td>--</td></tr><tr><td style='border-bottom:none;'><strong>Corticosteroid Use</strong></td><td style='border-bottom:none;'></td></tr><tr><td>(%)</td><td>--</td></tr><tr><td>Median Duration, Days (Range)</td><td>--</td></tr><tr><td><strong>Other Treatments</strong></td><td>--</td></tr><tr><td><strong>Resolution<sup>&dagger;</sup> (%)</strong></td><td>--</td></tr><tr><td style='border-bottom-left-radius:5px;'><strong>Recurrence After <nobr>Re-Initiation</nobr> of OPDIVO (%)</strong></td><td style='border-bottom-right-radius:5px;'>--</td></tr></table><p style='font-size:12px!important;margin-bottom:5px;margin-top:15px;'><span style='display: inline-block;text-indent: -5px;'>*</span>The chart reflects exposure to OPDIVO as a single agent, for clinically significant adverse reactions in 1994 patients across select approved indications. Please see OPDIVO <a href='http://packageinserts.bms.com/pi/pi_opdivo.pdf' target='_blank' style='font-weight:bold;color:#003B5C;'>US Full Prescribing Information</a> for full safety information.</p><p style='font-size:12px!important;'><span style='display: inline-block;text-indent: -5px;'><sup>&dagger;</sup></span>In the context of the IMAE time-to-resolution analyses, resolution date was defined as the <nobr>investigator-assessed</nobr> IMAE resolution date. In the analyses of complete resolution, complete resolution was defined as improved to Grade 0 or baseline grade per investigator assessment with completion of corticosteroid treatment (or other medical intervention).</p><p style='font-size:12px!important;'><span style='display: inline-block;text-indent: -5px;'><sup>&Dagger;</sup></span>At least 40 mg prednisone equivalent per day.</p><p style='font-size:12px!important;'><span style='display: inline-block;text-indent: -5px;'><sup>&sect;</sup></span>Complete resolution following CS taper.</p><p style='font-size:12px!important;'><span style='display: inline-block;text-indent: -5px;'><sup>||</sup></span>Complete resolution following CS use.</p><p style='font-size:12px!important;'>CS=corticosteroids; HRT=hormone-replacement therapy; mo/mos=month/months; IMAE=immune-mediated adverse event.</p>",
                                    "What selected safety profile topic would you like to explore?"
                                ],
                                "suggest": [
                                    405,
                                    406,
                                    407,
                                    400
                                ]
                            },
                            {
                                "id": 600,
                                "title": "Summary and Exit",
                                "prompt": [
                                    "That's all for now."
                                ],
                                "answer": [
                                    "<img class='avatar' style='width: 30px; position:absolute;' src='http://c.mdchat-usa.com/assets/images/edels/casey_1.gif'/><div style='margin-left:40px;'>Thank you for reviewing this information about OPDIVO<sup>&reg;</sup> in patients previously treated with mNSCLC.</div>",
                                    "Here's a summary of what we reviewed:",
                                    "<objectives>"
                                ],
                                "suggest": []
                            },
                            {
                                "id": 700,
                                "title": "<a style='color:white;' href='https://d.mdchat-usa.com/130201338/p1/casey?pkey=42337dea03e_07cb_4382_ad15_71'>Start from the beginning</a>",
                                "prompt": [
                                    "That's all for now."
                                ],
                                "answer": [
                                    "Click <a href='https://d.mdchat-usa.com/130201338/p1/casey?pkey=42337dea03e_07cb_4382_ad15_71'>here</a> to start from the beginning."
                                ],
                                "suggest": []
                            }
                        ],
                        "objectives": {
                            "1": "In previously treated non-squamous NSCLC, OPDIVO achieved a significantly higher OS vs Chemotherapy*, with over half of patients alive at 1 year (51% vs 39%). <reference id='1'>[OPDIVO PI]</reference> <reference id='2'>[Borghaei]</reference> Also, OPDIVO demonstrated longer median OS of 17.1 months vs 9.0 months with chemotherapy* for patients expressing <nobr>PD-L1</nobr> at all levels (&ge;1%).<sup>&dagger;</sup> <reference id='1'>[OPDIVO PI]</reference><p></p><p>HR for OS=0.73 (95% CI: 0.60-0.89; <em>P</em>=0.0015). Median OS was 12.2 months (95% CI: 9.7-15.0) for OPDIVO and 9.4 months (95% CI: 8.0-10.7) for docetaxel.</p><p>78% of patients had quantifiable PD-L1 expression (n=455/582). PD-L1 non-expressors were defined as <1% of tumor cells expressing PD-L1 (n=209) and PD-L1 expressors were defined as ≥1% of tumor cells expressing PD-L1&nbsp;(n=246).</p><p>OPDIVO reduced the risk of death by 41% in patients expressing PD-L1 at all levels (≥1%) (95% CI:&nbsp;0.43-0.82).</p><p>&#60;1% (n=209): HR=0.90 (95% CI: 0.66-1.24); median OS=10.4 months with OPDIVO vs. 10.1&nbsp;months with chemotherapy.*</p><p>ORR with OPDIVO was 19% (56/292; 4 complete responses) (95% CI: 15-24) vs 12% (36/290; 1&nbsp;complete response) with docetaxel (95% CI: 9-17); <em>P</em>=0.02. The median duration of response was 17 months in the OPDIVO arm (95% CI:&nbsp;8.4-NR) and 6 months in the docetaxel arm (95% CI:&nbsp;4.4-7.0).</p><p>Median PFS with OPDIVO was 2.3&nbsp;months vs 4.2&nbsp;months with docetaxel; HR=0.92, (95% CI: 0.77-1.11); <nobr><em>P</em>=0.39.</nobr></p><p>Checkmate 057 results were based on the prespecified interim analysis conducted when 413&nbsp;events (93% of the planned number of events for final analysis) were observed (190 in the OPDIVO arm and 223 in the docetaxel&nbsp;arm).</p>",
                            "2": "<p>In previously treated squamous NSCLC, OPDIVO delivered 50% longer median OS vs chemotherapy* (9.2 vs 6.0 months) in a study designed to include PD-L1 expressors and non-expressors.<reference id='1'>[OPDIVO PI]</reference> OPDIVO is the first and only PD-1 inhibitor to nearly double 1-year overall survival rate vs. chemotherapy.* <reference id='1'>[OPDIVO PI]</reference> <reference id='3'>[Brahmer]</reference></p><p>ORR with OPDIVO was 20% (27/135; 1 complete response) (95% CI: 14-28) vs 9% (12/137; 0 complete responses) with docetaxel (95% CI: 5-15); <em>P</em>=0.0083. The median duration of response was NR in the OPDIVO arm (95% CI: 9.8-NR) and 8.4&nbsp;months in the docetaxel arm (95% CI:&nbsp;3.6-10.8).</p><p>Median PFS with OPDIVO was 3.5 months vs 2.8 months with docetaxel; HR=0.62 (95% CI:&nbsp;0.47-0.81); <nobr><em>P</em>=0.0004.</nobr></p><p>Results were based on the prespecified interim analysis conducted when 199&nbsp;events (86% of the planned number of events for final analysis) were observed (86 in the OPDIVO arm and 113 in the docetaxel&nbsp;arm).</p><p>PD-L1 expression level did not impact the OS benefit observed with OPDIVO vs chemotherapy* in squamous&nbsp;mNSCLC.</p>",
                            "3": "<p>With a q4w (480-mg) dosing option, OPDIVO<sup>&reg;</sup> is the only immuno-oncology therapy with flexible dosing schedules to help meet the needs of your patients. <reference id='1'>[OPDIVO PI]</reference> <reference id='6'>[Long]</reference>  <br>Adverse reactions may be managed with treatment modifications. <reference id='1'>[OPDIVO PI]</reference></p>",
                            "4": "<p>In Checkmate 017 and 057, serious adverse reactions occurred in 46% of patients receiving OPDIVO (n=418). The most frequent serious adverse reactions reported in &ge;2% of patients receiving OPDIVO were pneumonia, pulmonary embolism, dyspnea, pyrexia, pleural effusion, pneumonitis, and respiratory failure. <reference id='1'>[OPDIVO PI]</reference></p><p>In <nobr>Checkmate 017</nobr> and 057, the most common adverse reactions (≥20%) in patients receiving OPDIVO (n=418) were fatigue, musculoskeletal pain, cough, dyspnea, and decreased appetite. <reference id='1'>[OPDIVO PI]</reference></p><p style='font-size:12px!important;'>*Docetaxel</p><div style='transform:translate(7px)'><div style='transform:translate(-7px, -1px);font-size:12px;position:absolute;'><sup>&dagger;</sup></div><p style='font-size:12px!important;margin-bottom:5px;'><strong>Median overall survival in patients treated with OPDIVO who had a <nobr>PD-L1</nobr> expression level of ≥1%, ≥5%, or ≥10%.</strong></p></div>"
                        },
                        "progress": {
                            "display": false
                        },
                        "settings": {
                            "header": {
                                "title": "",
                                "image": "https://c.mdchat-usa.com/programs/130201338/img/logo.svg"
                            },
                            "classesSet": {
                                "botReply": "primary-color-bg dark-grey-color-font",
                                "mecbotBackground": "white-color-bg",
                                "chatBackground": "white-color-bg",
                                "suggestion": "secondary-color-bg white-color-font",
                                "userMessage": "third-color-bg white-color-font"
                            }
                        }
                    }
                }
            ]
        }
    }
}
